KR20040017355A - Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease - Google Patents

Abstract

The present invention relates to a compound of formula (1). The present invention also relates to a process for the preparation of the compound of formula (I), a pharmaceutical composition containing the same, and a method for the use thereof, in particular for the control of autoimmune diseases.

<Formula 1>

In the formula,

R ¹ and R ² are each independently C _1-6 alkyl, C _3-6 alkenyl, C _3-6 cycloalkylC _1-3 alkyl or C _3-6 cycloalkyl, each of which is optionally 1 to 3 May be substituted with a halogen atom;

R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;

Q is -CO- or -C (R ⁴ ) (R ⁵ )-, wherein R ⁴ is a hydrogen atom or C _1-4 alkyl and R ⁵ is a hydrogen atom or a hydroxy group;

Ar is a 5-10 membered aromatic ring system in which up to 4 ring atoms can independently be heteroatoms selected from nitrogen, oxygen and sulfur, and the ring system is optionally substituted with one or more substituents as defined herein.

Description

Thienopyrimidinedione and its use in the regulation of autoimmune diseases {Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease}

While T-cells play an important role in the immune response, T-cells in autoimmune diseases are inappropriately activated and proliferated for certain tissues, resulting in inflammation associated with, for example, rheumatoid arthritis. Inhibition of proliferation of T-cells is beneficial in the control of autoimmune diseases. The present invention relates to compounds which are beneficial in the control of autoimmune diseases.

The compounds of WO 2000/12514 and WO 2001/038489 are known to be useful for modulating immune responses. These applications include compounds having an amide -C-N- at position 5 of the thienopyrimidine ring system. These compounds exist as slow interconverting rotamers due to the combination of slow rotation around the amide CN bond and slow rotation around the bond from the amide carbonyl to the thienopyrimidine center, with the interconversion rate being It is the rate that can be separated by HPLC. Such non-rotating rotations are a serious problem in the development of pharmaceutical compounds. That is, a long equilibrium time means that different initial rotamer mixtures can be formed if the conditions of the final stage of the synthesis are changed, which leads to problems in purity analysis and regeneration of the solid formulation of the raw drug. In addition, rotameomeric forms with lifespans similar to biological half-lives can be processed by different ways of metabolic processes that can form structurally different metabolites, so that all biological activity and stability must be fully studied and recorded. The inventors have found a group of compounds in the present invention comprising an amide-CN- group at position 5 of the thienopyrimidine ring system and having an advantageous effect but without problems associated with compounds present as separate rotamers under ambient conditions. It was.

The present invention relates to thieno [2,3-d] pyrimidinediones, methods for their preparation, pharmaceutical compositions containing them, and their use in therapy. In particular, the present invention relates to its use in the control of autoimmune diseases.

According to the present invention there is provided a compound of formula 1, or a pharmaceutically acceptable salt or prodrug thereof.

In the formula,

R ¹ and R ² are each independently C _1-6 alkyl, C _3-6 alkenyl, C _3-6 cycloalkylC _1-3 alkyl or C _3-6 cycloalkyl, each of which is optionally 1 to 3 May be substituted with a halogen atom;

R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;

Q is -CO- or -C (R ⁴ ) (R ⁵ )-, wherein R ⁴ is a hydrogen atom or C _1-4 alkyl and R ⁵ is a hydrogen atom or a hydroxy group;

Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo , Thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , hydroxy, C _1-4 alkylsulfonyl, C _1-4 alkylsulfinyl 5 or containing up to 4 heteroatoms selected from carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, and independently nitrogen, oxygen and sulfur; or A 5-10 membered aromatic ring system optionally substituted with one or more substituents selected from 6 membered aromatic rings;

p is 1 to 4;

R ⁶ and R ⁷ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring.

Another aspect of the invention relates to a compound of formula 1 or a pharmaceutically acceptable salt thereof as defined above.

In the present invention, it is to be understood that the compounds of formula (1) or salts thereof may exhibit tautomerism phenomena and the formula drawing herein may represent only one possible tautomeric form. It is to be understood that the present invention includes all tautomeric forms and is not limited to any one tautomeric form used in the structural formula. Structural formulas herein can represent only one possible tautomeric form, and it is to be understood that this specification includes all possible tautomeric forms, not just the forms that may be depicted herein.

The present invention relates to compounds of formula (1) as well as salts thereof as defined above. Salts used in pharmaceutical compositions may be pharmaceutically acceptable salts, but other salts may be useful in the preparation of compounds of Formula 1 and pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts of the invention include, for example, acid addition salts of compounds of formula 1 as defined above which are sufficiently basic to form such salts. Such acid addition salts are, for example, inorganic or organic acids providing pharmaceutically acceptable anions, for example hydrogen halides (especially hydrochloric or hydrobromic acid, particularly preferably hydrochloric acid) or sulfuric acid or phosphoric acid, or trifluoroacetic acid Salts with citric acid or maleic acid. Suitable salts include hydrochloride, hydrobromide, phosphate, sulfate, hydrogen sulfate, alkylsulfonate, arylsulfonate, acetate, benzoate, citrate, maleate, fumarate, succinate, lactate and tartrate. In addition, when the compound of Formula 1 is sufficiently acidic, a pharmaceutically acceptable salt may be formed with an inorganic or organic base that provides a pharmaceutically acceptable cation. Salts with such inorganic or organic bases are, for example, alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, ammonium salts such as methylamine, dimethylamine, Salts with trimethylamine, piperidine, morpholine or tris- (2-hydroxyethyl) amine.

Preferred salts are acid addition salts such as hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate or p-toluenesulfonate, or sodium or potassium salts. Alkali metal salts, such as.

Various forms of prodrugs are known in the art. See the following references for examples of such prodrug derivatives.

a) Design of Prodrugs, H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, K. Widder, et al. (Academic Press, 1985);

b) A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", H. Bundgaard, p. 113-191 (1991);

c) [H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);

d) [H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); And

e) [N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984)].

Examples of such prodrugs can be used to prepare in vivo cleavable esters of the compound of formula (I). In vivo hydrolyzable esters of compounds of formula 1 containing hydroxy groups are pharmaceutically acceptable esters which, for example, hydrolyze in human or animal bodies to form the parent alcohol. This includes inorganic acid esters such as phosphoric acid esters and α-acyloxyalkyl ethers, and related compounds that form the parent hydroxyl group by in vivo hydrolysis of the ester. α-acyloxyalkyl ethers include, for example, acetomethoxy and 2,2-dimethylpropionyloxymethoxy. Selections of hydrolyzable esters in vivo to form hydroxy groups include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (which forms alkyl carbonate esters), dialkylcarbamoyl and N- ( Dialkylaminoethyl) -N-alkylcarbamoyl (carbamate formation), dialkylaminoacetyl and carboxyacetyl.

In addition, it is to be understood that certain compounds of Formula 1 may exist in solvate form as well as in unsolvated form. It is to be understood that the present invention encompasses all solvate forms that are useful for treatment, in particular for the specific therapeutic purposes mentioned below.

Unless otherwise specified, the alkyl, alkenyl or alkynyl groups herein, or the alkyl, alkenyl or alkynyl moieties in the substituents may be linear or branched.

Ar may be bonded to a —C (R ⁴ ) (R ⁵ ) group by ring carbon or ring nitrogen when not quaternized.

In the group -C (R ⁴ ) (R ⁵ ) Ar, it will be appreciated that R ⁵ can be a hydroxy group only if Ar is bonded to -C (R ⁴ ) (R ⁵ ) via a carbon atom that is not a heteroatom. . It should also be understood that in -C (O) Ar, Ar is bonded to the -C (O) residue via a carbon atom that is not a heteroatom. Hydroxyalkyls may contain one or more hydroxy groups (preferably single hydroxy groups).

For clarity, when Ar is substituted with an oxo or thioxo group, Ar is intended to include aromatic dihydrides. For example, this includes thiazolyl and 2,3-dihydrothiazolyl when the latter is substituted with an oxo or thioxo group. Similarly, Ar is, for example, 2,3-dihydrobenzoxazolyl, 2,3-dihydrobenzothiazolyl, 2,3-dihydropyrazinyl and 2,3-dihydrobenzimidazolyl If substituted with an oxo or thioxo group).

Ar may be a heteroatom in which up to four ring atoms are independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups) (eg , Methyl, ethyl, n-propyl, n-butyl, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl or 3-hydroxypropyl), C _1-4 alkoxy (eg, methoxy, e Oxy, n-propoxy or n-butoxy), halogen (eg fluorine, chlorine, bromine or iodine), haloalkyl (eg fluoromethyl, chloromethyl, bromomethyl, 2-fluoro Ethyl, 2-fluoropropyl or 3-fluoropropyl), dihaloalkyl (eg, difluoromethyl, dichloromethyl, chlorofluoromethyl, dibromomethyl, 2,2-difluoroethyl, 2,2-difluoropropyl or 2,3-difluoropropyl), trihaloalkyl (eg, trifluoromethyl, trickle Romero naphthyl, 2,2,2-trifluoro-ethyl, 2,2,2-trifluoropropyl or 2,2,3- trifluoropropyl), C _1-4 alkoxy C _1-4 alkyl, a (for example, For example, methoxymethyl, ethoxymethyl, 2-methoxyethyl, 2-methoxypropyl or 3-methoxypropyl), C _1-4 alkylthio (eg, methylthio, ethylthio, n-propylthio Or n-butylthio), C _1-4 alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl or n-butoxycarbonyl), C _2-4 alkanoyl (eg acetyl or propionyl), oxo, thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ (eg amino, N -methylamino, N -ethyl Amino, di- N, N -methylamino or N -ethyl- N -methylamino),-(CH ₂ ) _p N (R ⁸ ) R ⁹ (eg CH ₂ N (R ⁸ ) R ⁹ ,- CH ₂ CH ₂ N (R ⁸ ) R ⁹ or CH ₂ CH ₂ CH ₂ N (R ⁸ ) R ⁹ ), hydroxy, C _1-4 alkylsulfonyl (eg, methylsulfonyl, ethyl Sulfonyl or propylsulfonyl), C _1-4 alkylsulfinyl (methylsulfinyl, ethylsulfinyl or propylsulfinyl), carbamoyl, C _1-4 alkylcarbamoyl (eg methylcarbamoyl , Ethylcarbamoyl and propylcarbamoyl), di-C _1-4 alkylcarbamoyl (eg, di-N, N-methylcarbamoyl, N-ethyl-N-methylcarbamoyl or di 5- or 6-membered aromatic rings containing up to 4 heteroatoms independently selected from -N, N-ethylcarbamoyl), carboxy, and nitrogen, oxygen and sulfur (e.g., phenyl, pyrimidyl, thienyl And furanyl); a 5-10 membered aromatic ring system optionally substituted with 1, 2, 3 or 4 substituents selected from.

The aromatic ring system can be monocyclic or polycyclic (eg bicyclic), for example phenyl, naphthyl, quinolyl, pyrazolyl, thienyl, oxazolyl, imidazolyl, pyridinyl, pi Rolo [2,3-b] pyridyl, benzimidazolyl, indazolyl, benzothiazolyl, 2,3-dihydrobenzothiazolyl, benzoxazolyl, thiazolyl, 2,3-dihydrothiazolyl, 2 , 3-dihydrobenzimidazolyl, 2,3-dihydrobenzoxazolyl, thiazolo [5,4-b] pyridyl and benzotriazolyl.

Another meaning of the substituents on R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ , R ⁹ , p, Q and Ar and Ar is further defined below. This meaning may be appropriately used in any of the definitions, claims, or embodiments defined below or above.

In one aspect, Ar is a 5 or 6 membered monocyclic ring.

In another aspect, Ar is an 8, 9 or 10 membered bicyclic ring.

In another aspect, Ar is a 9 or 10 membered bicyclic ring.

One aspect of the present invention provides 5 to 5 wherein Ar in Formula 1 contains up to 4 ring heteroatoms selected from nitrogen, oxygen and sulfur, provided that at least one ring nitrogen is present and the ring is optionally substituted as defined above. A compound which is a 10 membered aromatic ring system.

In another aspect, Ar is an optionally substituted 5-10 membered aromatic as defined above containing one or two ring nitrogen atoms and optionally one ring sulfur or oxygen atom, or containing three ring nitrogen atoms It is a ring system.

In another aspect, Ar is an optionally substituted 5-10 membered aromatic ring system as defined above containing one or two ring nitrogen atoms and optionally one ring sulfur atom.

In another aspect, Ar is an optionally substituted 5-10 membered aromatic ring system containing two ring nitrogen atoms.

In another aspect, Ar is imidazolyl, pyrazolyl, pyrrolyl, isoxazolyl, phenyl, quinolyl, indolyl, benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzoxazolyl, pyrrolo [2,3-b] pyridyl, imidazo [1,2-a] pyridyl, imidazo [4,5-b] pyridyl, 2,3- Dihydrothiazolo [5,4-b] pyridyl, 2,3-dihydropyrazinyl, 2,3-dihydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl.

In another aspect, Ar is imidazolyl, pyrazolyl, pyrrolyl, isoxazolyl, quinolyl, indolyl, benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2, 3-dihydrobenzoxazolyl, pyrrolo [2,3-b] pyridyl, imidazo [1,2-a] pyridyl, imidazo [4,5-b] pyridyl, 2,3-dihydro Thiazolo [5,4-b] pyridyl, 2,3-dihydropyrazinyl, 2,3-dihydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl.

In another aspect, Ar is imidazolyl, pyrazolyl, benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrobenzoxazolyl, pyrrolo [2,3-b] pyridyl, imidazo [1,2-a] pyridyl, imidazo [4,5-b] pyridyl, 2,3-dihydrothiazolo [5,4-b] pyridyl, 2,3-dihydropyrazinyl and 2 , 3-dihydrobenzimidazolyl.

More particularly, Ar is imidazolyl, quinolyl, indolyl, benzimidazolyl, indazolyl, pyrazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzoxazolyl, pi Rolo [2,3-b] pyridyl, thiazolo [5,4-b] pyridyl, 2,3-dihydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl.

In another aspect, Ar is selected from imidazolyl, pyrazolyl, pyrrolyl, isoxazolyl, phenyl and 2,3-dihydropyrazinyl.

In another aspect, Ar is quinolyl, indolyl, benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzoxazolyl, pyrrolo [2,3 -b] pyridyl, imidazo [1,2-a] pyridyl, imidazo [4,5-b] pyridyl, 2,3-dihydrothiazolo [5,4-b] pyridyl, 2, 3-dihydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl.

In another aspect, where the substituent on Ar is a 5 or 6 membered aromatic ring, this substituent on Ar independently contains up to 2 heteroatoms selected from nitrogen, oxygen and sulfur. In one aspect, it is selected from furanyl, thienyl, phenyl and pyrimidinyl. In another aspect, it is selected from pyrimidyl and phenyl. In another aspect, this is phenyl.

Examples of the ring type formed by the nitrogen atom to which they are attached together with R ⁶ and R ⁷ are pyrrolidino, piperidino, morpholino, piperazino, azephano, 1,4-oxephano and 1,4 It contains diazephano. In another aspect, this ring is selected from pyrrolidino, piperidino or morpholino.

Examples of ring types formed by the nitrogen atom to which they are attached together with R ⁸ and R ⁹ are pyrrolidino, piperidino, morpholino, piperazino, azepano, 1,4-oxephano and 1,4 It contains diazephano. In another aspect, this ring is selected from pyrrolidino, piperidino or morpholino.

R ¹ and R ² are each independently C _1-6 alkyl, eg C _1-5 alkyl (eg methyl, ethyl, n-propyl, 1 which may each be optionally substituted with 1 to 3 halogen atoms) -Methylethyl, n-butyl, 2-methylpropyl, 2,2-dimethylpropyl, n-pentyl or n-hexyl), C _3-6 alkenyl, for example C _3-4 alkenyl (eg, 1-propenyl, 1-butenyl, 1-pentenyl or 1-hexenyl), C _3-6 cycloalkylC _1-3 alkyl (cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, 2- (cyclopropyl) ) Ethyl, 2- (cyclobutyl) ethyl or 2- (cyclopentyl) ethyl) or C _3-6 cycloalkyl, for example C _5-6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) ( Trifluoromethyl 2,2,2-trifluoroethyl, 2-chloroethyl, 2-chloropropyl or 3,3,3-trifluoropropyl).

In another aspect, R ¹ and R ² are each independently C _1-5 alkyl or C _3-6 cycloalkylmethyl, each optionally substituted with 1 to 3 halogen atoms.

In another aspect, R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropylmethyl, trifluoromethyl 2,2,2-trifluoroethyl, 2-chloroethyl, 2-chloropropyl or 3,3,3-trifluoropropyl.

In another aspect, R ¹ is ethyl, n-propyl, isopropyl or 2-methylpropyl.

In another aspect, R ¹ is 2-methylpropyl.

In one aspect, R ² is methyl or trifluoromethyl.

In another aspect, R ² is methyl.

In another aspect, R ³ is hydroxyisoxazolidin-2-ylcarbonyl, tetrahydroisoxazine-2-yl or hydroxytetrahydroisoxazine-2-ylcarbonyl.

In another aspect, R ³ is hydroxyisoxazolidin-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl.

In another aspect, R ³ is hydroxyisoxazolidin-2-yl carbonyl.

In another aspect, R ³ is 4-hydroxyisoxazolidin-2-yl.

In another aspect, R ³ is 4S-hydroxyisoxazolidin-2-yl.

In another aspect, R ⁴ and R ⁵ are independently hydrogen or methyl.

In another aspect, Q is -CO- or -CH _2- .

In one aspect, Q is -CO-.

In another aspect Q is -CH _2- .

In another aspect, Ar is unsubstituted or substituted with 1, 2 or 3 substituents.

In another aspect, Ar is unsubstituted or substituted with 1 or 2 substituents.

In another aspect, the substituents for Ar are C _1-4 alkyl (optionally substituted with 1 or 2 hydroxy groups), C _1-4 alkoxy, halogen, trihaloalkyl, C _1-4 alkylthio, C _{2- 4} alkanoyl, oxo, thioxo, cyano and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , where p is 1 or 2, hydroxy, C _1-4 alkylsulfonyl, carbamoyl , C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, or a 5 or 6 membered aromatic ring containing up to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur It includes.

In certain aspects, substituents on Ar are C _1-4 alkyl, halogen, C _2-4 alkanoyl, trifluoromethyl, oxo, thioxo, hydroxyC _1-4 alkyl, amino, C _1-4 alkylamino And C _1-4 alkylthio.

In another aspect, the substituents for Ar are methyl, ethyl, n-propyl, isopropyl, tert-butyl, 1-methylethyl, trifluoromethyl, chloro, fluoro, bromo, hydroxymethyl, acetyl, methyl Thio, amino, methylamino, furanyl, thienyl, pyrimidyl, phenyl, cyano, thioxo and oxo.

In another aspect, the substituents for Ar are methyl, propyl, isopropyl, tert-butyl, 1-methylethyl, trifluoromethyl, chloro, fluoro, bromo, methylthio, amino, methylamino, phenyl, pyri Midyl, cyano, thioxo and oxo.

Another specific substituent for Ar is from methyl, ethyl, propyl, tert-butyl, 1-methylethyl, chloro, fluoro, bromo, hydroxymethyl, acetyl, methylthio, amino, methylamino, thioxo and oxo Is selected.

Another specific substituent for Ar is selected from methyl, ethyl, propyl, tert-butyl, fluoro, chloro, oxo, thioxo, hydroxymethyl, amino, methylamino and methylthio.

Another specific substituent for Ar is selected from methyl, propyl, tert-butyl, 1-methylethyl, chloro, fluoro, methylthio, amino, methylamino, thixo and oxo.

Specific examples for Ar include 4,5-dichloro-2-methylimidazol-1-yl, 4,5-dichloro-2-hydroxymethylimidazol-1-yl, 2,4,5-trichloro Ro-2-methylimidazol-1-yl, 4,5-dichloroimidazol-2-yl, 2-bromo-4,5-dichloroimidazol-2-yl, 2-methylthio-imidazole- 1-yl, 3,5-dimethylpyrazol-4-yl, 1,3,5-trimethylpyrazol-4-yl, 3,5-dimethylpyrazol-4-yl, 3-tert-butyl-5- Methylpyrazol-4-yl, 3,5-dimethylpyrazol-1-yl, 5-methyl-3-phenylpyrazol-4-yl, 5-methyl-3- (trifluoromethyl) pyrazol-4 -Yl, 5-methyl-3- (prop-2-yl) pyrazol-4-yl, 3,5-methyl-1-phenylpyrazol-4-yl, 5-dichloro-2,3-dihydro 2-oxothiazol-3-yl, 4-chloro-2,3-dihydro-2-oxothiazol-3-yl, 3,5-dimethylisoxazol-4-yl, 2,4-dimethyl -1- (prop-2-yl) pyrrole-3-yl, 2-trifluorophenyl, 2,3-dihydro-6-methyl-3-oxopyrazinyl, quinol-4-yl, quinol-5 -Yl, 6-fluoroquinol-4-yl, 8-fluoroquinol-4-yl, 2-methylquinol-4- 1, 2-methylindol-3-yl, 7-methylindol-3-yl, 5-cyanoindol-1-yl, 2-methylbenzimidazol-1-yl, 2-ethylbenzimidazole-1- 1, 2-propylbenzimidazol-1-yl, 2-methylthiobenzimidazol-1-yl, 2-hydroxymethylbenzimidazol-1-yl, 2-methylaminobenzimidazol-1-yl, 2-aminobenzimidazol-1-yl, pyrrolo [2,3-b] pyridin-3-yl, 2-methylpyrrolo [2,3-b] pyridin-1-yl, 2-methylpyrrolo [ 2,3-b] pyridin-3-yl, imidazo [1,2-a] pyrid-3-yl, 2- (methylthio) imidazo [4,5-b] pyrid-1-yl, 2- (methylthio) imidazo [4,5-b] pyrid-3-yl, 1H-1,2,3-benzotriazol-1-yl, 2-oxo-2,3-dihydrobenzothia Zol-3-yl, 2-thioxo-2,3-dihydrobenzothiazol-3-yl, 2-oxo-2,3-dihydrobenzoxazol-1-yl, 2-oxo-2,3- Dihydrobenzimidazol-3-yl, 2-oxo-2,3-dihydrobenzimidazol-1-yl, 5,6-difluoro-2-oxo-2,3-dihydrobenzimidazole- 1-yl and 2-oxo-1,3-thiazolo [5,4-b] pyridine-3- It includes.

Another specific example for Ar is 4,5-dichloro-2-methylimidazol-1-yl, 2,4,5-trichloro-2-methylimidazol-1-yl, 4,5- Dichloroimidazol-2-yl, 3,5-dimethylpyrazol-4-yl, 1,3,5-trimethylpyrazol-4-yl, 3,5-dimethylpyrazol-4-yl, 3-tert- Butyl-5-methylpyrazol-4-yl, 5-dichloro-2,3-dihydro-2-oxothiazol-3-yl, 4-chloro-2,3-dihydro-2-oxothiazole- 3-yl, quinol-4-yl, quinol-5-yl, 6-fluoroquinol-4-yl, 8-fluoroquinol-4-yl, 2-methylquinol-4-yl, 2-methylindole- 3-yl, 7-methylindol-3-yl, 5-cyanoindol-1-yl, 2-methylbenzimidazol-1-yl, 2-ethylbenzimidazol-1-yl, 2-propylbenzimi Dazol-1-yl, 2-methylthiobenzimidazol-1-yl, 2-hydroxymethylbenzimidazol-1-yl, 2-methylaminobenzimidazol-1-yl, 2-aminobenzimidazole- 1-yl, pyrrolo [2,3-b] pyridin-3-yl, 2-methylpyrrolo [2,3-b] pyridin-1-yl, 2-methylpyrrolo [2,3-b] pyridine -3-yl, 1H-1,2,3-benzotria -1-yl, 2-oxo-2,3-dihydrobenzothiazol-3-yl, 2-thioxo-2,3-dihydrobenzothiazol-3-yl, 2-oxo-2,3- Dihydrobenzoxazol-1-yl, 6-methyl-3-oxo-2,3-dihydropyrazin-2-yl and 2-oxo-1,3-thiazolo [5,4-b] pyridine-3- Includes work.

In one aspect, R ⁶ and R ⁷ are each independently a hydrogen atom, C _1-4 alkanoyl (eg formyl, acetyl or propionyl) or C _1-4 alkyl (eg methyl, ethyl, n -Propyl or n-butyl) or together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring.

In another aspect, R ⁶ and R ⁷ are each independently hydrogen atom or C _1-4 alkyl.

In one aspect, R ⁸ and R ⁹ are each independently a hydrogen atom, C _1-4 alkanoyl (eg, formyl, acetyl or propionyl) or C _1-4 alkyl (eg, methyl, ethyl, n -Propyl or n-butyl) or together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring.

In another aspect, R ⁸ and R ⁹ each independently represent a hydrogen atom or C _1-4 alkyl.

Certain groups of compounds,

R ¹ is C _1-5 alkyl or C _3-6 cycloalkylmethyl;

R ² is C _1-5 alkyl;

R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;

Q is -CO- or -CH _2- ;

Ar may be a heteroatom of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 alkoxy, Halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo, nitro , Cyano, a 5-10 membered aromatic ring system optionally substituted with 1, 2 or 3 substituents selected from -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ ;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is C _1-5 alkyl or C _3-6 cycloalkylmethyl;

R ² is C _1-5 alkyl;

R ³ is hydroxyisoxazine-2-ylcarbonyl, tetrahydroisoxazine-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar contains up to 4 ring heteroatoms selected from nitrogen, oxygen and sulfur, provided that at least one ring nitrogen is present and is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups) , C _1-4 alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _{2- 4} alkanoyl, oxo, thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , hydroxy, C _1-4 alkylsulfonyl, C _{1 -4} alkylsulfinyl, carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, and up to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur A 5-10 membered aromatic ring system optionally substituted with one or more substituents selected from 5 or 6 membered aromatic rings containing;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropylmethyl, trifluoromethyl 2,2,2-trifluoroethyl, 2-chloroethyl, 2-chloropropyl or 3,3,3-trifluoropropyl;

R ² is methyl;

R ³ is hydroxytetrahydroisoxazine-2-ylcarbonyl, tetrahydroisoxazine-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar contains up to 4 ring heteroatoms selected from nitrogen, oxygen and sulfur, provided that at least one ring nitrogen is present and the ring system is independently substituted with C _1-4 alkyl (optionally 1, 2 or 3 hydroxy groups C _1-4 alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo, thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , hydroxy, C _1-4 alkylsulfonyl, Up to ₄ C _1-4 alkylsulfinyl, carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, and independently selected from nitrogen, oxygen, and sulfur A 5-10 membered aromatic ring system optionally substituted with one or more substituents selected from 5 or 6 membered aromatic rings containing heteroatoms;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl or cyclopropylmethyl;

R ² is methyl;

R ³ is hydroxyisoxazolidin-2-ylcarbonyl, tetrahydroisoxazine-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl;

Q is -CH _2- ;

Ar independently contains up to 4 ring heteroatoms selected from nitrogen, oxygen and sulfur, provided that at least one ring nitrogen is present and the ring system is independently C _1-4 alkyl (optionally 1, 2 or 3 hydroxy groups Substituted), C _1-4 alkoxy, halogen, trihaloalkyl, C _1-4 alkylthio, C _2-4 alkanoyl, oxo, thioxo, cyano and-(CH ₂ ) _p N (R ⁸ R ⁹ (p is 1 or 2), hydroxy, C _1-4 alkylsulfonyl, carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy And a 5-10 membered aromatic ring system optionally substituted with 1 or 2 substituents independently selected from 5 or 6 membered aromatic rings containing up to 4 heteroatoms selected from nitrogen, oxygen and sulfur, Or a pharmaceutically acceptable salt thereof.

Another group of compounds,

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl or cyclopropylmethyl;

R ² is methyl;

R ³ is 4-hydroxytetrahydroisoxazine-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl;

Q is -CH _2- ;

Ar is each ring system independently methyl, ethyl, n-propyl, iso-propyl, tert-butyl, 1-methylethyl, trifluoromethyl, chloro, fluoro, bromo, hydroxymethyl, acetyl, methylthio Imidazolyl, pyrazolyl, pyrrolyl, isoxazolyl, optionally substituted with one or two substituents selected from amino, methylamino, furanyl, thienyl, pyrimidyl, phenyl, cyano, thioxo and oxo, Phenyl, quinolyl, indolyl, benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzoxazolyl, pyrrolo [2,3-b] pyridyl , Imidazo [1,2-a] pyridyl, imidazo [4,5-b] pyridyl, 2,3-dihydrothiazolo [5,4-b] pyridyl, 2,3-dihydropyra Compound of formula (I) selected from genyl, 2,3-dihydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl, or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention relates to a compound of formula 1, or a pharmaceutically acceptable salt or prodrug thereof.

<Formula 1>

In the formula,

R ¹ and R ² are each independently C _1-6 alkyl, C _3-6 alkenyl, C _3-5 cycloalkylC _1-3 alkyl or C _3-6 cycloalkyl, each of which is optionally 1 to 3 May be substituted with a halogen atom;

R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;

Q is -CO- or -C (R ⁴ ) (R ⁵ )-, wherein R ⁴ is a hydrogen atom or C _1-4 alkyl and R ⁵ is a hydrogen atom or a hydroxy group;

Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo , Thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , hydroxy, C _1-4 alkylsulfonyl, C _1-4 alkylsulfinyl , carbamoyl, C _1-4 alkyl-carbamoyl, di - (C _1-4 alkyl) carbamoyl, with at least one substituent selected from carboxy, optionally substituted 5- to 10-membered aromatic ring system, and;

p is 1 to 4;

R ⁶ and R ⁷ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring.

Certain groups of compounds,

R ¹ is C _1-5 alkyl or C _3-6 cycloalkylmethyl;

R ² is C _1-5 alkyl;

R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;

Ar may be a heteroatom of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo Is a 5-10 membered aromatic ring system optionally substituted with 1, 2 or 3 substituents selected from nitro, cyano, -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ ;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkanoyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is C _1-5 alkyl or C _3-6 cycloalkylmethyl;

R ² is methyl;

R ³ is hydroxyisoxazolidin-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo Is a 5-10 membered aromatic ring system optionally substituted with 1, 2 or 3 substituents selected from nitro, cyano, -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ ;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl or cyclopropylmethyl;

R ² is methyl;

R ³ is hydroxyisoxazolidin-2-ylcarbonyl or hydroxytetrahydroisoxazine-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo , 5-10 membered aromatic ring system optionally substituted with 1, 2 or 3 substituents selected from thioxo, nitro, cyano, -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ ;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another particular group of compounds is

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl or cyclopropylmethyl;

R ² is methyl;

R ³ is hydroxyisoxazolidin-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo Is a 5-10 membered aromatic ring system optionally substituted with 1, 2 or 3 substituents selected from nitro, cyano, -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ ;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl or cyclopropylmethyl;

R ² is methyl;

R ³ is hydroxyisoxazolidin-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar is each ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _{1- 4} alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo, nitro, cyano, -NR ⁶ R ⁷ and -CH ₂ NR ⁸ R ⁹ Imidazolyl, pyrazolyl, 2,3-dihydrothiazolyl, quinolyl, indolyl, benzimidazolyl, indazolyl, pyrrolo [2,3- optionally substituted with one, two or three substituents selected from b] pyridinyl, 1H-1,2,3-benzotriazolyl, 2,3-dihydrobenzothiazolyl, 2,3-dihydrobenzimidazolyl, 2,3-dihydrobenzoxazolyl and 1, 3-thiazolo [5,4-b] pyridinyl;

R ⁶ and R ⁷ are each independently hydrogen or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring;

R ⁸ and R ⁹ are each independently a hydrogen atom or C _1-4 alkyl, or a compound of formula (1) forming a 5 to 7 membered saturated heterocyclic ring with the nitrogen atom to which they are attached, or a pharmaceutically acceptable It is a salt.

Another group of compounds,

R ¹ is n-propyl, 1-methylethyl or 2-methylpropyl;

R ² is methyl;

R ³ is 4-hydroxyisoxazolidin-2-ylcarbonyl;

Q is -CO- or -CH _2- ;

Ar is optionally substituted with one, two or three substituents each ring system is independently selected from methyl, ethyl, propyl, tert-butyl, chloro, fluoro, thioxo, hydroxymethyl, methylthio, amino, methylamino and oxo Substituted imidazolyl, pyrazolyl, 2,3-dihydrothiazolyl, quinolyl, indolyl, benzimidazolyl, pyrrolo [2,3-b] pyridinyl, 1H-1,2,3-benzo A compound of formula 1 selected from triazolyl, 2,3-dihydrobenzothiazolyl, 2,3-dihydrobenzoxazolyl and 1,3-thiazolo [5,4-b] pyridinyl, or a pharmaceutical thereof Are acceptable salts.

Certain compounds of the present invention,

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione;

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylcarbonyl) thieno [2 , 3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- (2- Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(1H-pyrrolo [2,3-b] Pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) carbonyl] -1- (2 -Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (1-methylethyl) -6- (1H-pyrrolo [2,3-b] pyridine -3-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [4,5-dichloro-2-oxo-3 (2H) -thiazolylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1 -(2-methylpropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1-isobutyl-3 Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1-isobutyl-3-methyl-6- [1,3,5-trimethyl-1H-pyrazol-4-yl Methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(R) -6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl) methyl] -5- [4-hydroxy-isoxazolidin-2-ylcarbonyl]- 3-methyl-1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-benzimidazol-1-yl) methyl] -1- ( 2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6-[(2-ethyl-1H-benzimidazol-1-yl) methyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- ( 2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-propyl-1H-benzimidazole-1 -Yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2- (methylthio) -1H-benzimidazole -1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-amino-1H-benzimidazol-1-ylmethyl] -1- (2- Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2,4,5-trichloro-1H- Imidazol-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2-thioxo-3 (2H) benzothiazolyl Methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [4-chloro-2-oxo-3 (2H) -Thiazolylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- [2-oxo-1,3-benzoxazole-3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6-[(2-oxo [1,3] thiazolo [ 5,4-b] pyridin-1 (2H) -yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (1H-1,2,3-benzotriazole- 1-ylmethyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (1H-pyrrolo [2,3-b] pyridine -1-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -1- [1,2,3,4-tetrahydro-5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -2 , 4-dioxothieno [2,3-d] pyrimidin-6-ylmethyl) -1H-indole-5-carbonitrile;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- [2-oxo-1,3-benzothiazole- 3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (2-methylpropyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (2-methylpropyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridine-3 -Ylmethyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (1-methylethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1- (1-methylethyl) thieno [2,3-d] pyrimidine-5-carboxamide;

(S) -6- [3,5-diethyl-1H-pyrazol-4-ylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- ( 2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [3- (1,1-dimethylethyl) -5-methyl-1H-pyrazol-4-ylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl- 3-methyl-1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2-methyl-4-quinolinylmethyl] thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [6-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [8-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- (5-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1-propyl-6- (quinolin-4-ylmethyl) thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione;

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (1-methylethyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3-oxo -Pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl) -1H-pyrrolo [2,3-b] pyridine-3- Yl) methyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -Propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- [2-amino-1H-benzimidazol-1-ylmethyl] -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(Isopropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-amino-1H-benzimidazol-1-ylmethyl ] Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl]- 3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (iso Butyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3- Methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propylthier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isopropyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

(S) -6- [3,5-dimethylisoxazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl]- 3-methyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl ) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-oxo-3 (2H) benzothiazolylmethyl] -thieno [ 2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] pyridine- 3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [5-cyano-1H-indol-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -6- [1-isopropyl-3,5-dimethyl-1H-pyrazole-4- Ylmethyl] -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl-6- [5-methyl-3-phenyl-1H-pyrazole-4 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-3-methyl-6- [5-methyl-3- (trifluoromethyl) -1H-pyra Zol-4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-6- [3-isopropyl-5-methyl-1H-pyrazol-4-ylmethyl]- 3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl- 1-propylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- (1H-1,2,3-benzotriazol-1-ylmethyl) -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl)- Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl) -6-[(2-oxothiazolo [5,4-b] pyridine-1 (2H ) -Yl) methyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (Isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [5,6-difluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxy-2-isoxazole Ridinylcarbonyl] -3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

3-methyl-6- [2-methylindol-3-ylmethyl] -1- (isobutyl) -5- (tetrahydroisoxazine-2-ylcarbonyl) -thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione;

6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [4, 5-b] pyridin-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -3H-imidazo [4,5-b] Pyridin-3-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -1- (iso Propyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (trifluoromethyl) phenylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione;

5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazole-1- Ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; And

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3-oxo -Pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione, and pharmaceutically acceptable salts thereof.

Synthesis of Compound of Formula 1

Compounds of formula (1) are outlined below and can be prepared by a number of methods, as described in more detail in the Examples below. The novel process for preparing the compound of formula 1 is provided as another feature of the present invention and as described below. Essential starting materials can be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in the additional non-limiting examples. In addition, the necessary starting materials are obtainable by procedures similar to those exemplified, which are within the ordinary skill of organic chemists.

Accordingly, according to another aspect of the present invention, the compound of formula 1 may be prepared by deprotecting the compound of formula 1 in which at least one functional group is protected. For example, amino or hydroxy groups may be protected during the series of reactions used to prepare the compound of Formula 1.

Generally, the protecting group is selected from any group described in the literature or known to the skilled chemist, suitable for protecting the group, and can be introduced by conventional methods.

The protecting group may be removed by any conventional method as described in the literature or known to the skilled chemist, suitable for removing the protecting group, which method minimizes interference with other groups in the molecule and It is selected so that it can be removed.

Suitable protecting groups for hydroxy groups are, for example, arylmethyl groups (particularly benzyl), tri- (1-4C) alkylsilyl groups (particularly trimethylsilyl or tert-butyldimethylsilyl), aryldi- (1-4C) alkyl Silyl groups (particularly dimethylphenylsilyl), diaryl- (1-4C) alkylsilyl groups (particularly tert-butyldiphenylsilyl), (1-4C) alkyl groups (particularly methyl), (2-4C) alkenes And a (1-4C) alkoxymethyl group (particularly methoxymethyl) or a tetrahydropyranyl group (particularly tetrahydropyran-2-yl). The deprotection conditions for the protecting group will inevitably change depending on the choice of protecting group. Thus, for example, an arylmethyl group, such as a benzyl group, can be removed by hydrogenation on a catalyst such as, for example, palladium on charcoal. In addition, trialkylsilyl or aryldialkylsilyl groups, for example tert-butyldimethylsilyl or dimethylphenylsilyl groups, are for example suitable acids such as hydrochloric acid, sulfuric acid, phosphoric acid or trifluoroacetic acid, or alkali metal or fluorine. It can be removed by treatment with ammonium fluoride, for example sodium fluoride, or in particular tetrabutylammonium fluoride. In addition, the alkyl group may be treated with, for example, an alkali metal (1-4C) alkyl sulfide, for example sodium thioethoxide, or, for example, with an alkali metal diarylphosphide, for example lithium diphenylphosphide. Or by treatment with, for example, boron trihalide or aluminum, for example boron tribromide. In addition, the (1-4C) alkoxymethyl group or tetrahydropyranyl group can be removed by treatment with a suitable acid such as hydrochloric acid or trifluoroacetic acid, for example.

In addition, suitable protecting groups for hydroxy groups are, for example, acyl groups, for example (2-4C) alkanoyl groups (particularly acetyl) or aroyl groups (particularly benzoyl). The deprotection conditions for the protecting group will inevitably change depending on the choice of protecting group. Thus, for example, acyl groups such as alkanoyl groups or aroyl groups can be removed by hydrolysis using suitable bases such as, for example, alkali metal hydroxides (for example lithium hydroxide or sodium hydroxide).

Suitable protecting groups for amino, imino or alkylamino groups are, for example, acyl groups, for example (2-4C) alkanoyl groups (particularly acetyl), (1-4C) alkoxycarbonyl groups (particularly methoxycarboxes) Carbonyl, ethoxycarbonyl or tert-butoxycarbonyl), arylmethoxycarbonyl groups (especially benzyloxycarbonyl) or aroyl groups (especially benzoyl). The deprotection conditions for the protecting group necessarily change depending on the choice of protecting group. Thus, for example, acyl groups such as alkanoyl, alkoxycarbonyl or aroyl groups are removed by hydrolysis using suitable bases such as, for example, alkali metal hydroxides (for example lithium hydroxide or sodium hydroxide). can do. Also, acyl groups such as tert-butoxycarbonyl groups can be removed by treatment with a suitable acid such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups such as benzyloxycarbonyl groups For example, it can be removed by hydrogenation over a catalyst such as palladium on charcoal.

Protection and deprotection of functional groups is described in [ 'Protective Groups in Organic Chemistry' , JWF McOmie, Plenum Press (1973)] and [ 'Protective Groups in Organic Synthesis' , 2 nd edition; TW Greene and PGM Wuts, Wiley-Interscience (1991).

The compound of formula 1, or a compound of formula 1 wherein at least one functional group is protected,

a) a method of reacting a compound of formula 10 with isoxazolidine or tetrahydroisoxazine, each optionally substituted with one hydroxy group;

b) when Q is methylene, reacting a compound of Formula 11 with a compound of Formula Ar;

c) when Q is methylene, reducing the compound of formula 12;

d) a process for preparing Ar by primary ring synthesis by reacting a compound of formula 11 or 13;

e) a method of reacting a compound of Formula 14 with R ¹ -L ²

Which may be prepared using any one of the compounds of Formula 1 and optionally after method a), b), c) or d), convert the compound of Formula 1 to another compound of Formula 1 and / or a pharmaceutically acceptable salt thereof Solvates can be prepared.

Wherein L and L ² are leaving groups and R ¹ , R ² , R ³ , Q and Ar are as defined above.

The reaction of the compound of formula 10 with isoxazolidine or tetrahydroisoxazine (optionally substituted with one hydroxy group) is conveniently carried out under amide bond formation reaction conditions. For example, it is carried out in the presence of a coupling agent such as dicyclohexylcarbodiimide or 1-ethyl-3- (3-dimethylaminopropyl) ethylcarbodiimide. Optionally, bases, especially organic bases such as triethylamine, can be used. Typically, suitable solvents are aprotic solvents such as dimethylformamide, or chlorinated solvents such as dichloromethane or trichloromethane. It is also possible to use compounds which catalyze this type of amide bond formation reaction, for example 1-hydroxybenzotriazole. Typically, the temperature is in the range of about −30 ° C. to about 60 ° C., in particular at or near ambient temperature.

Typically, the reaction of Ar with a compound of Formula 11 is carried out in the presence of a strong base such as sodium hydride. Suitable leaving groups are halo, especially bromo. This reaction is conveniently carried out in an inert solvent, for example tetrahydrofuran, in particular at or near ambient temperature. In some circumstances, for example, if Ar contains a ring nitrogen atom that does not need to be deprotected, a mild base such as sodium bicarbonate may be used. This reaction is conveniently used to make compounds in which Ar is bonded via a ring nitrogen atom. However, this method cannot be used to prepare compounds in which Ar is bonded via a ring carbon atom. This can be achieved by using strong bases and zinc salts, for example zinc chloride, and optionally sodium iodide as catalyst.

The compound of formula 12 may be reduced to the corresponding methylene compound using standard reducing conditions for hydroxy groups known in the art. For example, it can be protonated with an acid such as trifluoroacetic acid and reduced with trialkylsilane. It is also possible to use a catalyst such as palladium on charcoal to convert hydroxy groups to stronger leaving groups such as mesylate or tosylate, at temperatures ranging from 0 ° C. to 50 ° C., in particular at ambient temperatures of 1 to 5 bar. The resulting compound can be hydrogenated in a non-hydroxyl solvent, in particular tetrahydrofuran.

The -Q-Ar group may be conveniently formed on the compound of Formula 11 or 13 by primary ring synthesis. Here, 'The Chemistry of Heterocyclic Compounds', EC Taylor and A. Weissberger (published by John Wiley and Sons) and 'Comprehensive Heterocyclic Chemistry', A. R Katritzky and C. W Rees (published by Pergamon Press ( Elsevier)] For example, the preparation of a compound of Formula 1 wherein Ar is 3,5-dimethylpyrazol-4-yl or 1,3,5-trimethylpyrazol-4-yl can be found in the Examples of Specific Examples. See 11 and 12.

The compound of formula 14 may be reacted with the compound of formula R ¹ -L ² in a temperature range of ambient to 170 ° C. in a bipolar aprotic solvent, for example DMF, in the presence of a mild base, for example potassium carbonate. Can be.

Compounds of Formula 1 may be prepared by chemically modifying another compound of Formula 1. For example, a compound in which Q in formula 1 is methylene may be oxidized to a compound in which Q in carbon 1 is carbonyl. Preferred oxidizing agents are 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in an inert organic solvent such as tetrahydrofuran. In some circumstances, methylene compounds can be oxidized by exposure to air.

Intermediates of Formula 10 may be prepared from compounds of Formula 15 below.

Wherein R ²⁰ is C _1-6 alkyl, for example methyl or ethyl, and R ²¹ is —CH ₂ L where L is as defined above or —CH (OH) Ar.

Compounds in which R ^{21 in} formula 15 is —CH ₂ L may be reacted with Ar under conditions similar to those described in method b) above.

When Ar is bonded via a ring carbon atom, the compound in which R in formula 15 is -CH (OH) Ar can be reduced using conditions similar to those described in method c) above.

Compounds in which R ^{21 in} formula 12 or 15 is -CH (OH) Ar can be prepared by inactivating a compound of formula 16 in the presence of a strong base such as lithium dialkylamide, for example lithium diisopropylamide, such as tetrahydrofuran. In an organic solvent, it can be prepared by initially reacting with a compound of the formula Ar-CHO, initially at low temperature, for example -78 ° C, and then warming to ambient temperature.

Wherein R ²² is R ³ or —CO ₂ R ² where appropriate.

In general, intermediates are prepared from compounds of formula

In the formula, R ²³ is hydrogen or methyl.

When R ²¹ is —CH (OH) Ar, R ²³ is hydrogen and the compound of formula 16 may be reacted with Ar—CHO as described above for Formula 15.

When R ²¹ is -CH ₂ L, R ²³ is methyl, which is converted to -CH ₂ L by, for example, a halogenation reaction. When L is bromo, the methyl group can be brominated using standard brominating agents such as N-bromosuccinimide under standard conditions.

The compound wherein R ^{23 in} formula 17 is hydrogen may be prepared by first combining the compound of formula 18 in a polar solvent such as DMF in the presence of a mild base such as alkali carbonate such as potassium carbonate. After reaction with an alkylbromopyruvate, for example ethylbromopyruvate, at a temperature of 50 ° C., the resulting adduct is reacted in an inert solvent such as dichloromethane, between -20 ° C. and 50 ° C., in particular between 0 ° C. and It can be prepared by treatment with Lewis acid, in particular titanium tetrachloride, at a temperature of 25 ° C.

Compounds in which R ^{23 in the} formula (17) is methyl are prepared by first preparing the compound of formula (18) in a polar solvent such as DMF, or especially water, in the presence of a mild base such as an alkali carboxylate such as sodium acetate, After reaction with alkyl 3-bromo-2-oxobutanoate, for example methyl 3-bromo-2-oxobutanoate, at a temperature of from 5 ° C. to 50 ° C., the resulting adduct is then reacted with an inert solvent, eg For example, it can be produced by treatment with Lewis acid, in particular titanium tetrachloride, at a temperature of -20 ° C to 50 ° C, especially 0 ° C to 25 ° C, in dichloromethane.

The compound of formula 17 is reacted with an acetyl cyanate at a temperature of 0 ° C. to 50 ° C. in an inert solvent such as toluene, followed by the conversion of the compound of formula R ² -L ¹ , wherein L ¹ can be prepared by treatment with a solution of a metal alkoxide (eg, sodium methoxide in methanol) in an alkanol at a temperature of 0 ° C. to 30 ° C. in the presence of a compound of a leaving group, for example iodine.

_Wherein R ²⁴ is C _1-4 alkyl, for example ethyl.

The compound of formula 19 is reacted with a Wittig compound, for example, a compound of formula 21, in an inert solvent such as THF at a temperature of 20 ° C. to 80 ° C., resulting in situ addition The product may be prepared by treating with a compound of formula 22 at a temperature of -78 ℃ to 60 ℃.

R ¹ -N = S

The compound of formula 18 may be prepared by reacting a compound of formula 23 with an alkali metal thiol such as sodium thiol in a polar solvent such as an alcohol such as ethanol at a temperature ranging from 10 ° C. to 50 ° C.

The compound of formula 23 may be prepared by reacting a compound of formula 24 with a compound of formula R ¹ -L ² under the conditions described for method e) above.

The compound of Formula 1 may be converted into a pharmaceutically acceptable salt or prodrug thereof.

Certain compounds of formula (1) may exist in stereoisomeric forms. It is to be understood that the present invention includes all geometric isomers of the compounds of Formula 1 and mixtures thereof including optical isomers and racemates.

Isomers may be analyzed or separated by conventional techniques, such as chromatography or fractional crystals. Enantiomers can be isolated by separating racemates or other mixtures of compounds using conventional techniques (eg, chiral high performance liquid chromatography (HPLC)). In addition, the desired optical isomers can be reacted with a suitable optically active starting material under conditions that will not result in racemization, or derivatized with, for example, homochiral acid, and then used in conventional methods (e.g., HPLC, silica Chromatographic phases) can be prepared by isolating diastereomeric derivatives or using achiral starting materials and chiral reagents. All stereoisomers are included within the scope of the present invention.

Compounds of the present invention can be isolated from their reaction mixtures using conventional techniques.

The compounds of the present invention are useful because they have pharmacological activity in humans and non-human animals. These are referred to as pharmaceuticals for use in autoimmune, inflammatory, proliferative and hyperproliferative diseases and immune mediated diseases such as rejection of transplantation organs or tissues and for (prevention) treatment of acquired immunodeficiency syndrome (AIDS).

Examples of these diseases are as follows.

(1) (respiratory) airway diseases: for example chronic obstructive pulmonary disease (COPD); Asthma, for example bronchial, allergic, endogenous, exogenous or dusty asthma, especially chronic or refractory asthma (eg terminal asthma or airway hyperresponsiveness); bronchitis; Acute, allergic, atrophic rhinitis or chronic rhinitis, such as caseosa rhinitis, hypertrophic rhinitis, purulent rhinitis, dry rhinitis or drug rhinitis; Membrane rhinitis, such as croupous, fibrin and pseudomembranous rhinitis and cutaneous rhinitis; Seasonal rhinitis, eg, rhinitis nervosa (hay fever) and vasomotor rhinitis; Sarcoidosis; Farmer's lung and related diseases, pulmonary fibrosis and idiopathic epileptic pneumonia;

(2) (bone and joint) rheumatoid arthritis, negative serum reactive spondyloarthropathy (eg ankylosing spondylitis, psoriatic arthritis or lighter disease), Bezette's disease, Sjogren's syndrome or systemic sclerosis;

(3) (skin) psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatitis, seborrheic dermatitis, lichen planus, pemphigus, blistered bleb, epidermal blister, urticaria, angiodermas, vasculitis, erythema, skin Eosinophilia, uveitis, alopecia areata and spring conjunctivitis;

(4) (Gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis and foods that affect distant (e.g. migraines, rhinitis or eczema) from the intestines allergy;

(5) (different tissue and systemic diseases) multiple sclerosis, atherosclerosis, AIDS, erythema lupus, systemic lupus, erythema, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilic fasciitis, HyperIgE syndrome, leprosy leprosy, sezary syndrome and idiopathic thrombocytopenic purpura;

(6) (allograft rejection reactions), for example, acute and chronic rejection following transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; And chronic graft versus host disease; And

(7) cancer.

Accordingly, the present invention provides a compound of Formula 1 or a pharmaceutically acceptable salt thereof as defined above for use in therapy.

In another aspect, the present invention provides a compound of formula 1 or a pharmaceutically acceptable salt thereof as defined above for use in inhibiting proliferation of T cells.

In another aspect, the present invention provides the use of a compound of formula 1 or a pharmaceutically acceptable salt thereof as defined above in the manufacture of a medicament for inhibiting the proliferation of T cells.

As used herein, the term "treatment" also includes "prophylaxis" unless specifically stated otherwise. The terms "therapeutic" and "therapeutically" should be interpreted correspondingly.

Prophylaxis specifically refers to the treatment of a person who has suffered or is believed to be at increased risk for a previous episode of the disease or disorder. In general, a person at risk of developing a particular disease or condition includes a person with a family history of the disease or condition, or a person identified by genetic testing or screening, in particular, having a high probability of developing the disease or condition. .

In addition, the invention includes administering to a patient a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof as defined above (eg, in the treatment of allograft rejection) Provide a method of inhibition.

In addition, the present invention is suffering from an airway disease (eg, asthma or COPD), comprising administering to a patient a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof as defined above; or A method of treating or reducing the risk of a patient at risk for such a disease is provided.

Of course, for such therapeutic uses, the dosage will vary depending on the compound used, the mode of administration, the desired treatment and the disorder indicated. In general, however, the daily dose of the compound of formula 1 for immunosuppression is between 0.1 mg / kg and 30 mg / kg, in particular between 0.3 mg / kg and 30 mg / kg, more particularly between 0.5 mg / kg and 30 mg / kg. kg, even more particularly 1 mg / kg to 30 mg / kg. Typically, the daily dose of Formula 1 for the treatment of airway disease will range from 0.001 mg / kg to 30 mg / kg.

Compounds of formula (1) and their pharmaceutically acceptable salts may be used alone, but are generally pharmaceuticals in which the compound / salt / solvate (active ingredient) of formula (1) is included with a pharmaceutically acceptable adjuvant, diluent or carrier It will be administered in the form of a composition. Depending on the mode of administration, the pharmaceutical composition will in particular comprise from 0.05 to 99% by weight, more in particular less than 80% by weight, for example 0.10 to 70% by weight and even more particularly less than 50% by weight, of all weight percent Is based on the total composition.

Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof as defined above together with a pharmaceutically acceptable adjuvant, diluent or carrier.

The present invention also provides a process for the preparation of a pharmaceutical composition of the present invention comprising mixing a compound of Formula 1 or a pharmaceutically acceptable salt thereof as defined above with a pharmaceutically acceptable adjuvant, diluent or carrier. .

Pharmaceutical compositions of the invention can be administered topically (eg, to the lungs and / or airways, or skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; For example, it may be administered orally in the form of tablets, capsules, syrups, powders or granules, or parenterally by parenteral administration in the form of solutions or suspensions, or rectally or subcutaneously in the form of subcutaneous or suppositories.

Inhibition of PMA / ionomycin stimulated peripheral blood mononuclear cell proliferation of a compound can be assessed using, for example, the procedure described below.

Inhibition of PMA / Ionomycin Stimulated Peripheral Blood Mononuclear Cell Proliferation

Assays for PMA / ionomycin stimulated PBMC proliferation were performed in 96-well flat bottom microtiter plates. The compound was prepared as a 10 mM stock solution in dimethyl sulfoxide. 50-fold dilutions thereof were prepared in RPMI, and serial dilutions were made from this solution. 10 μl of 50-fold dilution mother liquor or its dilutions were added to the wells and the assay concentration gradually decreased starting at 9.5 μM. In each well was placed 1 × 10 ⁵ PBMC in RPMI1640 medium supplemented with 10% human serum, 2 mM glutamine and penicillin / streptomycin, prepared from human peripheral blood of a single donor. Phorbol myristate acetate (PMA) (final concentration 0.5 ng / ml) and ionomycin (final concentration 5OO ng / ml) were added to the cells in supplemented RPMI1640 medium (as above) to give a final assay volume of 0.2 ml. It was made. Cells were incubated for 72 hours at 37 ° C. in a humid atmosphere of 5% carbon dioxide. ³ H-thymidine (0.5 μCi) was added during the last 6 hours of incubation. The radioactivity levels incorporated by the cells were then measured, which became a measure of proliferation.

The IA ₅₀ value of the compounds of the examples in this test was less than 1 × 10 ⁻⁶ M. In the specific examples below, the IA ₅₀ of Example 1 in the test was 1.7 × 10 ⁻¹ M and the IA ₅₀ of Example 20 was 5 × 10 ⁻⁹ M.

The invention will now be described in the following examples, unless otherwise indicated,

(i) evaporation was carried out by vacuum rotary evaporation and the workup procedure was carried out after the removal of residual solids, for example by filtration of the desiccant;

(ii) the operation was carried out under an inert gas such as argon or nitrogen atmosphere at ambient temperature in the range of 18 ° C. to 25 ° C.,

(iii) yields are shown by way of example only and are not necessarily the maximum value achievable;

(iv) The structure of the final product of Formula 1 was confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectrometry techniques. Proton magnetic resonance chemical shift values were measured in deltas and peak multiplicity was s (singlet): singlet; d (doublet): doublet; t (triplet): triplet; m (multiple): polyline; br (broad): wide; q (quartet): quadruple; quin (quintet): represented by quintet;

(v) In general, intermediates were not fully characterized and purity was determined by thin layer chromatography (TLC), high performance liquid chromatography (HPLC), mass spectrometry (MS), infrared (IR) or NMR analysis.

Abbreviation

2,3-dichloro-5,6-dicyano-1,4-benzoquinoneDDQ

Dimethylformamide DMF

m-chloroperoxybenzoic acid mCPBA

Tetrahydrofuran THF

Example 1

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (4-quinolinylmethyl) thieno [2,3- d] pyrimidine-2,4 (1H, 3H) -dione

a) (S) -methyl 2- [4-hydroxyisoxazolidin-2-yl] carbonylbenzoate

Triethylamine (0.28 ml) was added to a solution of N-hydroxyphthalimide (5.00 g) and (R)-(+)-epichlorohydrin (2.40 ml) in dioxane anhydride (10 ml) under nitrogen. The mixture was stirred at 50 ° C. for 48 hours, (R)-(+)-epichlorohydrin (0.24 ml) and triethylamine (0.28 ml) were added and stirring continued at 50 ° C. for 24 hours. . Methanol (10 ml) and triethylamine (4.27 ml) were added and stirring continued at 50 ° C. for 2 hours. This mixture was evaporated under reduced pressure and the residue was dissolved in saturated aqueous sodium bicarbonate solution (100 ml) and extracted with ethyl acetate (6 × 100 ml). The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was recrystallized from ethyl acetate to give the title compound (3.4 g).

b) (S) -4-isoxazolidinol hydrochloride

Hydrochloric acid (4 M, 15 ml) was added to the product of step a) (1.87 g) and the solution was heated to reflux for 3 hours. The mixture was cooled to rt, filtered and evaporated under reduced pressure. The residue was recrystallized from propan-2-ol to give the title compound as a white needle (0.78 g).

c) ethyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

6-mercapto-3-methyl-1- (isobutyl) -pyrimidine-2,4 (1H, 3H) -dione (49.5 g) is dissolved in dry DMF (900 ml) and ethyl bromopyruvate (30 ml) was added followed by addition of anhydrous potassium carbonate (15.95 g) with stirring. The mixture was stirred at rt for 5 h and then poured into water (5 L). The aqueous solution was acidified with dilute hydrochloric acid and then extracted completely with ethyl acetate. The organic extract was dried (MgSO ₄ ) and evaporated in high vacuum to give a semisolid mass. A portion of this semisolid mass (24 g) was dissolved in methylene chloride (500 ml) and cooled in an ice bath under a nitrogen atmosphere. Titanium tetrachloride (13.5 ml) was added slowly with good stirring. The reaction mixture was stirred in an ice bath for 1 hour and then at room temperature for 3 hours. The reaction mixture was poured slowly into vigorously stirred ice water (1.5 L) and then the resulting suspension was extracted into methylene chloride. To give the title compound as a pale yellow solid (15 g) -: (1 isohexane-ethyl acetate SiO _2/1) After drying, the vacuum was removed the organic solvent, and the residue chromatographed.

d) ethyl 1,2,3,4-tetrahydro-6- [hydroxy (4-quinolinyl) methyl] -3-methyl-1- (isobutyl) -2,4-dioxothieno [2 , 3-d] pyrimidine-5-carboxylate

A solution of lithium diisopropylamide (5.52 g) in anhydrous THF (80 ml) (8.02 g) and 4-quinolinecarboxaldehyde (8.12 g) in step c) in anhydrous THF (80 ml) at −78 ° C. under nitrogen. ) Was added dropwise over 1 hour to a stirred solution. The mixture is further stirred at −78 ° C. for 1 hour, then quenched with ice acetic acid (10 ml), warmed to room temperature, diluted with saturated sodium bicarbonate solution (100 ml) and ethyl acetate (2 × 100 ml) Extracted into. The combined extracts were dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography eluting with 3: 2 ethyl acetate / i-hexane to give the title compound as a white solid (7.35 g).

e) ethyl 1,2,3,4-tetrahydro-3-methyl-1-isobutyl) -2,4-dioxo-6- (4-quinolinylmethyl) -thieno [2,3-d ] Pyrimidine-5-carboxylate

Trifluoroacetic anhydride (3.33 ml) was added to a solution of the product of step d) (7.34 g) and triethylamine (6.56 ml) in dry THF (150 ml) at room temperature under nitrogen and the mixture was stirred for 15 minutes. Palladium on charcoal 10% (500 mg) was added and the mixture was hydrogenated at 1 bar for 20 hours. This was washed with saturated sodium bicarbonate solution (150 ml), then ethyl acetate (300 ml) and filtered through celite. The organic material was extracted into ethyl acetate (150 ml) and the combined extracts were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluting with 1: 1 ethyl acetate / i-hexane to give the title compound as a solid (5.90 g).

f) sodium 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (4-quinolinylmethyl) -thieno [2,3- d] pyrimidine-5-carboxylate

The product of step e) (5.89 g) in THF (150 ml) and methanol (23 ml) was degassed by repeated exhaust and nitrogen flush under nitrogen. 1 M sodium hydroxide (18 ml) was added and the mixture was stirred for 18 hours. The resulting precipitated solid was collected by filtration, washed with THF and dried in vacuo to give the title compound as a solid (5.06 g).

g) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione

To the product (157 mg) suspension of step f) in dichloromethane (5 ml) was added 1-hydroxybenzotriazole hydrate (108 mg) and the mixture was stirred for 15 minutes. 1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide hydrochloride (135 mg) was added and stirring continued for 1 hour. (S) -4-isoxazolidinol hydrochloride (Example 1, Part b)) (69 mg) and triethylamine (147 μl) were added and the reaction mixture was stirred for 18 hours, then concentrated under reduced pressure I was. The residue was eluted with i-hexane / ethyl acetate (10-100% gradient) and purified by column chromatography to give the title compound as a solid (136 mg).

Example 2

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (4-quinolinylmethyl) thieno [2,3- d] pyrimidine-2,4 (1H, 3H) -dione

a) (R) -methyl 2- [4-hydroxyisoxazolidin-2-ylcarbonyl] benzoate

Prepared from N-hydroxyphthalimide and (S)-(+)-epichlorohydrin according to the method of Example 1, part a).

b) (R) -4-isoxazolidinol hydrochloride

Prepared from the product of step a) following the procedure of Example 1b).

c) (R) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-1- (isobutyl) -6- (4-quinolinylmethyl) thieno [ 2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Hydroxybenzotriazole (90 mg) was added to a stirred suspension of the product (200 mg) from Example 1, part f) in dichloromethane (8 ml), followed by 1-ethyl-3- (3'-dimethylamino Propyl) carbodiimide hydrochloride (128 mg) was added. After 15 minutes, (R) -4-isoxazolidinol hydrochloride (84 mg) and triethylamine (0.093 ml) were added and stirring continued for 18 hours. The resulting mixture was purified by column chromatography on silica eluting with ethyl acetate / methanol (19: 1) and the product triturated with ether to give the title compound as a white powder (92 mg).

Example 3

(S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3,6-dimethyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

6-mercapto-3-methyl-1- (isobutyl) -pyrimidine-2,4 (1H, 3H) -dione (50 g) is dissolved in a solution of sodium acetate (95.6 g) in water (1.5 L) , Methyl 3-bromo-2-oxo-butanoate (44.6 g) was added dropwise with stirring. After stirring for 1 hour at room temperature, the mixture was extracted into ethyl acetate. This organic solution was washed with brine, dried (MgSO ₄ ) and evaporated to give an oil. This oil (75.1 g) was dissolved in methylene chloride (800 ml) and cooled in an ice bath under a nitrogen atmosphere. Titanium tetrachloride (43.3 ml) was slowly added dropwise while stirring well. The reaction mixture was stirred in an ice bath for 1 hour and then at room temperature for 3 hours. The reaction mixture was poured slowly into vigorously stirred ice water (2 L) and then the resulting suspension was extracted into methylene chloride. After drying, the organic solvent removed in vacuo, the residue chromatographed (SiO _2/1: 1 ethyl acetate-isohexane) to give the title compound, 42 g. Trituration with isohexane gave a white powder.

b) methyl 6- (bromomethyl) -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-thieno [2,3-d] pyrid Midine-5-carboxylate

The solution of product of step a) (10 g) and N-bromosuccinimide (5.74 g) in chloroform (350 ml) was refluxed under tungsten lamp irradiation for 4 hours. The solution was washed with water, saturated sodium bicarbonate and then brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by flash silica chromatography eluting with isohexane: ether (1: 1) to afford the title compound as a white powder (8.29 g).

c) methyl 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2 , 4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

4,5-dichloro-2-methylimidazole (1.3 g) in dry tetrahydrofuran (20 ml) was added to a suspension of sodium hydride (0.34 g, 60%) in dry tetrahydrofuran (20 ml) at room temperature under nitrogen. Added dropwise. After 15 minutes, a solution of the product of step b) (3.35 g) in dry tetrahydrofuran (20 ml) was added dropwise and the reaction stirred at room temperature for 3 hours. This solution was poured into water and extracted with ethyl acetate. The combined extracts were dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by flash silica chromatography, gradient eluting with 50-100% ethyl acetate in isohexane, to give the title compound as a white solid (2.28 g).

d) 6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl) methyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl)- 2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide (7.3 ml of 1 M aqueous solution), then methanol (4 ml) was added to a solution of the product of step c) (2.28 g) in tetrahydrofuran (50 ml) and stirred at room temperature for 3 hours. This solution was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The combined extracts were dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by flash silica chromatography, gradient eluting with 2-5% ethanol in dichloromethane to give the title compound as a white solid (1.68 g).

e) 6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl) methyl] -5- [4- (S) -hydroxy-2-isoxazolidinylcarbonyl]- 3-methyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared according to the method of Example 1, part g).

Example 4

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (4-quinolinylcarbonyl) thieno [2,3 -d] pyrimidine-2,4 (1H, 3H) -dione

Prepared from the product of Example 1, part b) (115 mg) and the product of Example 1, part f) according to the method of Example 1 g), and then exposing the product to air for 18 hours. It was. The crude material was eluted with aqueous ammonium acetate / acetonitrile and purified by reverse phase preparative HPLC, then triturated with ether to give the title compound as a white powder (22 mg).

( ^* NB material is present as a mixture of rotamers, so NMR is complex at room temperature but simplified at elevated temperature)

Example 5

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- (isobutyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- (isobutyl) -2,4-dioxo Thieno [2,3-d] pyrimidine-5-carboxylate

The solution of Example 3, part a) (7 g) and N-bromosuccinimide (4.42 g) in chloroform (140 ml) was refluxed under tungsten lamp irradiation for 2 hours. The solution was cooled to room temperature, saturated aqueous sodium bicarbonate solution (140 ml) and 2-methylindole (5.92 g) were added and the mixture was quickly stirred for 48 hours. The phases were separated and the aqueous phase was extracted with dichloromethane (100 ml). The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with ethyl acetate / i-hexane (1: 3) to give the title compound as a pale brown solid (6.68 g).

b) 1,2,3,4-tetrahydro-3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- (isobutyl) -2,4-dioxothier No [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide solution (1 M, 13.6 ml) and methanol (25 ml) were added to a stirred solution of the product of step a) (4 g) in tetrahydrofuran (100 ml). After 28 h, the solution was concentrated to 20 ml volume under reduced pressure, diluted with water (200 ml) and extracted with ether (2 × 100 ml). Concentrated hydrochloric acid was added to acidify the aqueous phase to pH 2 and extracted with ethyl acetate / methanol (19: 1, 2 × 200 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the title compound as a white solid (4 g).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 1, part g) from the product of part b) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b) to obtain the title compound as a solid.

Example 6

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(1H-pyrrolo [2,3-b] pyridine- 3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1 (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylate

2.5 M n-butyl lithium (2.6 ml) was added dropwise to a 7-azaindole (0.78 g) solution in dry THF (30 ml) under nitrogen at 10 ° C. and the resulting mixture was stirred for 15 minutes. 1.O M etheric zinc chloride (6.61 ml) was added and the mixture was allowed to warm to room temperature and stirred for 2 hours. The solvent was removed under reduced pressure and the residue was diluted with dry toluene (20 ml). After addition of a solution of Example 3, part b) (3.14 g) in dry toluene (10 ml), a catalytic amount of sodium iodide was added and the mixture was stirred under nitrogen for 72 hours. The solvent was decanted and the solid residue was partitioned between 2 N hydrochloric acid and ethyl acetate and the organic phase basified with sodium bicarbonate and extracted into ethyl acetate (2 x 100 ml). The combined extracts were dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography, eluting with i-hexane / ethyl acetate (20% to 75% gradient) to give the title compound as a yellow solid (1.37 g).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of step a) according to the method of Example 3, step d).

c) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-1- (isobutyl) -6-[(1H-pyrrolo [2,3- b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound (55 mg) was prepared from the product of step b (150 mg) and (S) -4-hydroxyisoxazolidine of Example 1, part b) according to the method of Example 1, step g).

Example 7

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) carbonyl] -1- (iso Butyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

2,3-dichloro-5,6-dicyano-1,4-benzoquinone (48 mg) of 48 mg of the product of Example 5, part c) in tetrahydrofuran / water (9: 1, 1 ml) It was added to the stirred solution. After 1 h the solution was evaporated under reduced pressure and the residue was eluted with aqueous ammonium acetate / acetonitrile gradient and purified by reverse phase preparative HPLC to recrystallize from ether to give the title compound as a solid (20 mg).

Example 8

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (1-methylethyl) -6- (1H-pyrrolo [2,3-b] pyridine -3-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) ethyl methyl 2-methyl-5- (N, N-methylethylamino) -thiophene-3,4-dicarboxylate

Ethoxycarbonylmethylene triphenyl phosphoran (33.8 g) in dry THF (200 ml) was treated with isopropyl isothiocyanate (10.1 g) at 65 ° C. under nitrogen for 16 hours. The mixture was cooled to -78 ° C and methyl 3-bromo-2-oxo-butanoate was added. The reaction was slowly warmed to room temperature. After 24 h at rt, further methyl3-bromo-2-oxo-butanoate (2.8 g) was added and the mixture was warmed to 60 ° C. for 16 h. The cooled reaction was poured into water (1.5 L) and extracted into ether. Was the title compound (23.5 g), dried and evaporated to give an oil, this was purified by chromatography (ethyl acetate:: 1 isohexane SiO _2/10 1 isohexane-ethyl acetate, and then 5).

b) methyl 1,2,3,4-tetrahydro-3,6-dimethyl-1- (1-methylethyl) -2,4-dioxo-thieno [2,3-d] pyrimidine-5- Carboxylate

Silver cyanate (13.5 g) suspended in anhydrous toluene (90 ml) under nitrogen was treated dropwise with acetyl chloride (5.34 ml) and stirred vigorously for 30 minutes. The product (23 g) of step 1) dissolved in anhydrous toluene (15 ml) was added and the mixture was stirred for 72 hours. Ether (360 ml) was added and the insoluble material was filtered off and washed with a small volume of ether. The combined organic solutions were washed with saturated sodium bicarbonate solution, dried and evaporated. The residue was treated with a solution of sodium methoxide (25% by weight, 64 ml) in methanol for 72 hours at room temperature. The reaction was ice cooled, treated with trimethylsilyl chloride (50.8 ml) and stirred overnight at room temperature. All volatiles were removed in vacuo and the residue was partitioned between water and ethyl acetate. The main component was isolated (12.2 g) the organic solution was dried and purified by the residue after the evaporation by chromatography (ethyl acetate: 2 isohexane SiO _2/2 1 isohexane-ethyl acetate, and then 3). This was treated with potassium carbonate (6.95 g) and methyl iodide (7.1 g) in dry DMF (150 ml) at room temperature for 72 hours. The mixture was poured into water (2 L), acidified and extracted into ether. Washing with brine, drying and evaporation gave a solid, which was boiled in isohexane (200 ml) containing ethyl acetate (3 ml). Cool to precipitate the pale yellow solid which was collected and dried to give the title compound (10.5 g).

c) 6- (bromomethyl) -1,2,3,4-tetrahydro-3-methyl-1- (1-methylethyl) -2,4-dioxothieno [2,3-d] pyrid Midine-5-carboxylic acid methyl ester

The title compound was prepared from the product of part b) using the procedure described in Example 3, part b).

d) 1,2,3,4-tetrahydro-3-methyl-1- (1-methylethyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridine-3 -Ylmethyl) thieno [2,3-d] pyrimidine-5-carboxylic acid methyl ester

The title compound was prepared from the product of part c) using the procedure described in Example 6, part a).

e) 1,2,3,4-tetrahydro-3-methyl-1- (1-methylethyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridine-3 -Ylmethyl) thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part d) using the procedure described in Example 3, part d).

f) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-1- (1-methylethyl) -6- (1H-pyrrolo [2,3 -b] pyridin-3-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part e) using the procedure described in Example 3, part e).

Example 9

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6-mercapto-3-methyl-1-propyl-pyrimidine-2,4 (lH 3H) -dione

A mixture of 6-chloro-3-methyl-1-propyl-pyrimidine-2,4 (1H, 3H) -dione (3.76 g), sodium hydrosulfide hydrate (6 g) and ethanol (100 ml) was added at room temperature After stirring for 48 hours, it was concentrated in vacuo. The residue was dissolved in water (500 ml) and washed with ethyl acetate (2 x 100 ml). The aqueous phase was acidified with dilute hydrochloric acid and then extracted with ethyl acetate (3 x 100 ml). The combined organic phases were dried (MgSO ₄ ) and evaporated to yield a pale yellow solid which was used directly in the next step.

b) methyl 1,2,3,4-tetrahydro-3,6-dimethyl-2,4-dioxo-1-propylthieno [2,3-d] pyrimidine-5-carboxylate

Prepared according to the procedure of Example 3, step a) from the product of step a).

c) 6- (bromomethyl) -1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propylthieno [2,3-d] pyrimidine-5-car Acid Methyl Ester

The title compound was prepared from the product of part b) using the procedure described in Example 3, part b).

d) 1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl) thier No [2,3-d] pyrimidine-5-carboxylic acid methyl ester

The title compound was prepared from the product of part c) using the procedure described in Example 6, part a).

e) 1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl) thier No [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part d) using the procedure described in Example 3, part d).

f) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-1-propyl-6- (1H-pyrrolo [2,3-b] pyridine- 3-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part e) using the procedure described in Example 3, part e).

Example 10

(S) -6- [4,5-dichloro-2-oxo- (2H) -thiazol-3-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3- Methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3,6-dimethyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared using the product of Example 3, step a) following the method of Example 3, step d).

b) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3,6-dimethyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2, 4 (1H, 3H) -dione

The title compound was prepared using the product of step a) according to the method of Example 1, step g).

c) (S) -5- [4-[(1,1-dimethylethyl) dimethylsilyloxy] isoxazolidin-2-ylcarbonyl] -3,6-dimethyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

To the solution of the product of step b) (1.2 g) and imidazole (0.24 g) in dichloromethane (20 ml) was added tert-butyldimethylsilyl chloride (0.54 g). After stirring for 16 hours at ambient temperature, the mixture was washed with water and the organics were poured onto a Biotage column. Gradient eluting with 0% to 5% methanol in dichloromethane to afford the title compound as a colorless solid (1.55 g).

d) (S) -6- (bromomethyl) -5- [4-[(1,1-dimethylethyl) dimethylsilyloxy] isoxazolidin-2-ylcarbonyl] -3-methyl-1- (Isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of step c) according to the method of Example 3, step b).

e) (S) -6-[(4,5-dichloro-2-oxo-3 (2H) -thiazolyl) methyl] -5- [4-[(1,1-dimethylethyl) dimethylsilyloxy] Sazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of step d) and 4,5-dichloro-2-oxo-3 (2H) -thiazolone according to the method of Example 3, step c).

f) (S) -6-[(4,5-dichloro-2-oxo-3 (2H) -thiazolyl) methyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3 -Methyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

To a solution of the product of step e) (180 mg) in THF (5 ml) under nitrogen atmosphere was added glacial acetic acid (0.10 ml) followed by the addition of 1N tetrabutylammonium fluoride solution in THF (0.5 ml). After 16 h at ambient temperature, the mixture was neutralized with saturated sodium bicarbonate solution and extracted into ethyl acetate. The organics were washed with water and dried over magnesium sulfate. Concentration in vacuo gave a white solid which was purified by reverse phase HPLC to give the title compound as a white solid (100 mg).

Example 11

(S) -6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1-isobutyl-3 -Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro Thieno [2,3-d] pyrimidine-5-carboxylic acid

Potassium carbonate (3.55 g) and dichlorobis (triphenylphosphine) cobalt (II) (0.1 g) were the product of Example 3, part a) in dichloromethane (30 ml) under nitrogen (1 g) and 2,4 -To a stirred solution of pentanedione (2.64 ml). After 48 hours, aqueous hydrazine (35%, 2.33 ml) was added and the mixture was vigorously stirred for 1 hour, diluted with water (30 ml) and extracted with ethyl acetate (2 x 60 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with ethyl acetate. The product was dissolved in tetrahydrofuran (20 ml) and methanol (3 ml) and then treated with sodium hydroxide solution (1 M, 2.57 ml). After 3 days, the mixture was evaporated to about 5 ml under reduced pressure, diluted with water (25 ml) and extracted with ethyl acetate (25 ml). The aqueous phase was acidified with hydrochloric acid and extracted with ethyl acetate (3 x 25 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the title compound as a solid (0.23 g).

b) (S) -6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -5-{[4-hydroxyisoxazolidin-2-yl] carbonyl) -1- Isobutyl-3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was solids from the product of part a) (225 mg) and (S) -4-hydroxyisoxazolidine hydrochloride {Example 1, part b)} using the procedure described in Example 1, part g). Obtained as (98 mg).

Example 12

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1- (isobutyl) -3-methyl-6- [1,3,5-trimethyl-1H-pyrazole-4 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) (S) -6- (bromomethyl) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) thieno [2,3-d ] Pyrimidine-2,4 (1H, 3H) -dione

Prepared from the product of Example 10 part b) according to the method of Example 3, part b).

b) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6-[(1,3,5-trimethyl-1H-pyra Zol-4-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The product of potassium tert-butoxide (1 M in tetrahydrofuran, 2.99 ml) in tetrahydrofuran (20 ml) at room temperature under nitrogen (1.OO g) and 2,4-pentanedione (0.31 ml) was added to the stirred solution. After 18 hours, 8 ml of this solution was treated with methylhydrazine (64 μl) and after 24 hours the mixture was evaporated under reduced pressure. The residue was purified by reverse phase preparative HPLC eluting with aqueous ammonium acetate / acetonitrile and then purified by column chromatography on silica eluting with ethyl acetate / methanol (24: 1) to give the title compound as a solid (24 mg). ).

Example 13 i)

(R) -6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl) methyl] -5- [4-hydroxy-isoxazolidin-2-ylcarbonyl]- 3-methyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the products of Example 3, part d) and Example 2, part b) according to the method of Example 1, part g).

Example 13 ii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6 [(2-methyl-1H-benzimidazol-1-yl) methyl] -1- (iso Butyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-6 [(2-methyl-1H-benzimidazol-1-yl) methyl] -1- (isobutyl) -2,4-dioxo Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepared from the product of Example 3, part b) and 2-methylbenzimidazole using the procedure described in Example 3, part c).

b) 1,2,3,4-tetrahydro-3-methyl-6 [(2-methyl-1H-benzimidazol-1-yl) methyl] -1- (isobutyl) -2,4-dioxo Thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-6-[(2-methyl-1H-benzimidazol-1-yl) methyl] -1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) using the procedure described in Example 3, part e).

Example 13 iii)

(S) -6-[(2-ethyl-1H-benzimidazol-1-yl) methyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6-[(2-ethyl-1H-benzimidazol-1-yl) methyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound is prepared from the product of Example 3, part b) and 2-ethylbenzimidazole using the procedure described in Example 3, part c), eluting with 30% to 70% ethyl acetate in isohexane Purification by flash silica chromatography.

b) 6-[(2-ethyl-1H-benzimidazol-1-yl) methyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -6 [(2-ethyl-1H-benzimidazol-1-yl) methyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of part b) using the procedure described in Example 3, part e), eluting with 5% methanol in ethyl acetate and purifying by flash silica chromatography, then recrystallization from ethyl acetate / isohexane to give the title compound. It was.

Example 13 iv)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(2-propyl-1H-benzimidazol-1-yl ) Methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6-[(2-propyl-1H-benzimidazol-1-yl) methyl ] Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Flashing chromatography eluting with isohexane: ethyl acetate (1: 1) from the product of Example 3, part b) and 2-n-propylbenzimidazole using the procedure described in Example 3, part c) After purification the title compound was obtained.

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6-[(2-propyl-1H-benzimidazol-1-yl) methyl ] Thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of step a) using the procedure described in Example 1, part f).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(2-propyl-1H-benzimidazole-1 -Yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of step b) and (S) -4-hydroxyisoxalidine hydrochloride [Example 1, Part b) using the procedure described in Example 3, part e).

Example 13 v)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-benzimidazole-1 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-benzimidazol-1-ylmethyl] -2,4 -Dioxothieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared from the product of Example 3, part b) and 2-methylthiobenzimidazole using the procedure described in Example 3, part c).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-benzimidazol-1-ylmethyl] -2,4- Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was obtained as a white solid from the product of step a) using the procedure described in Example 1, part f).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-benzimidazole -1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) and (S) -4-isoxazolidinol hydrochloride using the procedure described in Example 3, part e).

Example 13 vi)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1- (isobutyl) -2,4 -Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 3, part b) product (0.6 g) was dissolved in DMF (5 ml). 2-hydroxymethyl-benzimidazole (0.28 g) and anhydrous potassium carbonate (0.6 g) were added to this solution and stirred for 16 hours. The reaction mixture was filtered and evaporated to afford the title compound as a white solid (0.18 g).

b) 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1- (isobutyl) -2,4 -Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl -1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of Example, part b) using the procedure described in Example 3, part e).

Example 13 vii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (isobutyl) -2,4- Dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Sodium hydride (60% in mineral oil, 0.24 g) was partially added to a stirred solution of 2- (methylamino) benzimidazole (0.93 g) in DMF (50 ml) at 0 ° C. under nitrogen. After stirring for 30 minutes at room temperature, a solution of the product of Example 3, part b) (2.16 g) in DMF (10 ml) was added dropwise and the reaction stirred at room temperature for 16 hours. This solution was poured into water and extracted with ethyl acetate. The combined extracts were dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was recrystallized from ethyl acetate to give the title compound as a white solid (1.5 g).

b) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (isobutyl) -2,4- Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared using the product of part a) following the procedure of Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl]- 1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

(S) -4-hydroxyisosalidine hydrochloride (Example 1, Part b)) (0.08 g) and triethylamine (0.09 ml) of the product of part b) in dichloromethane (5 ml) (0.13 g ) Solution. 1-hydroxybenzotriazole (0.09 g) and 1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide hydrochloride (0.12 g) were added. The reaction mixture was stirred at rt for 12 h. This solution was concentrated under reduced pressure. The residue was purified by flash silica chromatography, gradient eluting with 0% to 3% methanol in ethyl acetate. The obtained product was recrystallized from ethyl acetate / isohexane / methanol to give the title compound as a white solid (0.07 g).

Example 13 viii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-amino-1H-benzimidazol-1-ylmethyl] -1- (isobutyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6-[(2-amino-1 H-benzimidazol-1-yl) methyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 13 The title compound was prepared from the product of Example 3, part b) (0.4 g) and 2-aminobenzimidazole (0.16 g) according to the method of vii), part a).

b) 6-[(2-amino-1 H-benzimidazol-1-yl) methyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the method of Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-amino-1 H-benzimidazol-1-ylmethyl] -1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 13 vii) The title compound was prepared from the product of part b) according to the method of part c).

Example 13 ix)

(S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6 [(2,4,5-trichloro-1H-imidazole- 1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2,4,5-trichloro-1H-imidazole-1 -Ylmethyl] thieno [2,3-d] pyrimidine-5-carboxylate

Chromatography (SiO ₂ /20% to 50% ethyl acetate-) using 2,4,5-trichloro-imidazole and the product of Example 3, part b) according to the method of Example 3, part c) Isohexane) to give the title compound.

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2,4,5-trichloro-1H-imidazole-1- Ylmethyl] thieno [2,3-d] pyrimidine-5-carboxylic acid

The product of part a) (170 mg) was treated with lithium hydroxide monohydrate (31 mg) in water (0.75 ml), methanol (0.75 ml) and THF (2.25 ml) for 4 hours at room temperature. Acidified and evaporated to dryness. The residue was dissolved in water and extracted into dichloromethane. Drying and evaporation gave the title compound (110 mg).

c) (S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [4,5-trichloro-1H-imidazole- 1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of step b) according to the method of Example 1, step g).

Example 13 x)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2-thioxo-3 (2H) -benzothiazolylmethyl ] Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2-thioxo-3 (2H) -benzothiazolylmethyl] Thieno [2,3-d] pyrimidine-5-carboxylate

The solution of Example 3, step b) (300 mg) and 2-methylthiobenzothiazole (300 mg) in diglyme (3 ml) was heated to 160 ° C. with microwave irradiation (600 W). After 30 minutes, the solvent was removed by vacuum distillation and the residue was purified by gradient chromatography eluting with dichloromethane to 5% methanol in dichloromethane to give the title compound as a white solid (150 mg).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-)-6-[(2-thioxo-3 (2H) benzothiazolyl) Methyl] thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared using the product of step a) according to the method of Example 3, step d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6 [(2-thioxo-3 (2H) -benzothia Zolyl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the method of Example 3, step e) and the product of step b).

Example 13 xi)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [4-chloro-2-oxo-3 (2H) -thia Zolylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 4-chloro-2-fluorothiazole

A suspension of 2,4-dichlorothiazole (5 g) and potassium fluoride (5 g) in tetramethylenesulfone (20 ml) was heated at 130 ° C. for 6 hours. Potassium fluoride (5 g) was further added and the mixture was heated at 175 ° C. for 16 h. The reaction mixture was vacuum distilled to give the title compound as colorless oil (1.7 g).

b) 4-chloro-2 (3H) -thiazolone

A mixture of the product of step a) (1.7 g) and potassium hydroxide (1.22 g) in water (25 ml) and acetonitrile (5 ml) was stirred at ambient temperature for 16 hours. The mixture was partitioned between water and dichloromethane, the aqueous layer was collected, acidified with ice-like acetic acid and extracted into dichloromethane. After drying over magnesium sulfate, the organics were filtered and concentrated to dryness to afford the title compound as a colorless oil (0.35 g).

c) methyl 6- [4-chloro-2-oxo-3 (2H) -thiazolylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4- Dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared using the product of step b) according to the method of Example 3, part c).

d) 6- [4-chloro-2-oxo-3 (2H) -thiazolylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared using the product of step c) according to the method of Example 3, part d).

e) (S) -6- [4-chloro-2-oxo-3 (2H) -thiazolylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1 -(Isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of step d) according to the method of Example 3, part e).

Example 13 xii)

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- [2-oxo-1,3-benzoxazole-3 (2H ) -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6-[(2-oxo-1,3-benzoxazole-3 (2H ) -Yl) methyl] thieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared using the product of Example 3, part b) and 1,3-benzoxazol-2 (3H) -one according to the method of Example 3, part c).

b) sodium 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2-oxo-1,3-benzoxazole-3 (2H) -Ylmethyl] -thieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared using the product of part a) according to the method of Example 3, part d).

c) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- [2-oxo-1,3-benzoxazole-3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of part b) according to the method of Example 3, part e).

Example 13 xiii)

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6-[(2-oxo [1,3] thiazolo [5, 4-b] pyridin-1 (2H) -yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 3-nitropyridine-2-thiol

To a solution of 3-nitro-2-chloropyridine (9.07 g) in ethanol (120 ml) was added NaSH (6.41 g) and the mixture was stirred for 30 minutes and then concentrated in vacuo. Water was added to the residue, acidified with diluted HCl and extracted with ethyl acetate (x5). The organic phase was washed with water, dried and concentrated in vacuo to give the title compound as an orange solid (9.08 g).

b)

The organic phase was dried in vacuo and concentrated to afford the title compound as dark green oil (0.29 g).

c) [1,3] thiazolo [5,4-b] pyridin-2 (1H) -one

To a solution of the product of b) (280 mg) in toluene (300 ml) was added 1,1-carbonyldiimidazole (392 mg) and heated to reflux for 16 h. The reaction mixture was concentrated in vacuo and the residue was eluted with an iso-hexane: ethyl acetate (3: 2) mixture and purified by normal chromatography. The combined organic fractions were concentrated in vacuo to afford the title compound as an off-white solid (214 mg).

d) methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6-[(2-oxo [1,3] thiazolo [5,4 -b] pyridin-1 (2H) -yl) methyl] thieno [2,3-d] pyrimidine-5-carboxylate

Prepared using the product of Example 3, part b) and the product of part c) using the method of Example 3, part c).

e) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2-oxo [1,3] thiazolo- [5,4- b] pyridin-1 (2H) -ylmethyl] -thieno [2,3-d] pyrimidine-5-carboxylic acid

Example 3, using the product of part d) using the method of part d).

f) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- [2-oxo [1,3] thiazolo [5 , 4-b] pyridin-1 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 3, using the product of part e) using the method of part e).

Example 13 xiv)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (1H-1,2,3-benzotriazole-1- Ylmethyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- (1H-1,2,3-benzotriazol-1-ylmethyl) -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 3, part b) and the product of benzotriazole using the procedure described in Example 3, part c).

MS (ESI) 309 [M-benzotriazole] ⁺

b) 6- (1H-1,2,3-benzotriazol-1-ylmethyl) -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-di Oxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (1H-1,2,3-benzotriazole- 1-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) using the procedure described in Example 1, part g).

Example 13 xv)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (1H-pyrrolo [2,3-b] pyridine-1 -Ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-1-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 3, part b) and 7-azaindole using the procedure described in Example 3, part c).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-1-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- (1H-pyrrolo [2,3-b] pyridine -1-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) using the procedure described in Example 3, part e).

Example 13 xvi)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(2-methyl-1H-pyrrolo [2,3- b] pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-1-ylmethyl]- 2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 3, part b) and 2-methyl-7-azaindole using the procedure described in Example 3, part c).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-1-ylmethyl]- 2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

MS (ESI) 427 [M + H] ⁺

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2-methyl-1H-pyrrolo [2,3 -b] pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) using the procedure described in Example 3, part e).

Example 13 xvii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [5-cyano- (1H) -indol-1-yl Methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [5-cyano-1H-indol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepare the title compound from the product of Example 3, part b) and 5-cyanoindole using the procedure described in Example 3, part c), which is eluted with 40% ethyl acetate in isohexane and flash silica chromatography Purification with

b) 6- [5-cyano-1H-indol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-thier No [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [5-cyano- (1H) -indole-1 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of part b) using the procedure described in Example 3, part e), the title compound was obtained after purification by flash silica chromatography eluting with 0% to 2% methanol in ethyl acetate.

Example 13 xviii)

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- [2-oxo-1,3-benzothiazole-3 ( 2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2-oxo-3 (2H) -benzothiazolylmethyl] thier No [2,3-d] pyrimidine-5-carboxylate

Example 3 The title compound was prepared using the product of Example 3 step b) and benzothiazolone according to the method of step c).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2-oxo-3 (2H) -benzthiazolylmethyl] thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared using the product of step a) according to the method of Example 3, step d).

c) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- [2-oxo-1,3-benzothiazole- 3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of step b) according to the method of Example 1, step g).

Example 13 xix)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3-oxo -Pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-6- [2,3-dihydro-6-methyl-3-oxo-pyrazin-2-ylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared using the method of Example 3, part c) from the product of Example 3, part b) and 2,3-dihydro-6-methyl-3-oxo-pyrazine. The crude product was purified by chromatography (SiO ₂ / EtOAc).

b) 1,2,3,4-tetrahydro-6- [2,3-dihydro-6-methyl-3-oxo-pyrazin-2-ylmethyl] -3-methyl-1- (isobutyl)- 2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The product of step a) was hydrolyzed according to the method of Example 1, part f). The crude product was dried in vacuo and used without further characterization.

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3 -Oxo-pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The crude product of step b) was reacted with (S) -4-hydroxyisoxazolidine hydrochloride using the method of Example 1, part g) to prepare the title compound. The crude product was purified by reverse phase HPLC using gradient elution (75% aqueous ammonium acetate / 25% acetonitrile to 100% acetonitrile).

Example 14 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [7-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-6- [7-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) -2,4-dioxothieno [ 2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared using the product of Example 3, part b) and 7-methyl indole according to the method of Example 5, part a).

b) 1,2,3,4-tetrahydro-3-methyl-6- [7-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) -2,4-dioxothieno [ 2,3-d] pyrimidine-5-carboxylic acid,

The title compound was prepared from the product of step a) using the procedure described in Example 1, part c).

c) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-6- [7-methyl-1H-indol-3-ylmethyl] -1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of step b) and (S) -4-hydroxyisoxazolidine hydrochloride [Example 1, Part b] using the procedure described in Example 1, part g), 0% to 3% in ethyl acetate Elution with methanol, purification by flash silica chromatography and recrystallization from ethyl acetate: isohexane (9: 1) gave the title compound.

Example 14 ii)

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1,2,3,4-tetrahydro-3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepared from the product of Example 3, part a) and 2-methylindole according to the method of Example 5, part a).

b) 1,2,3,4-tetrahydro-3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (isobutyl) -2,4-dioxothieno [ 2,3-d] pyrimidine-5-carboxylic acid

Prepared from the product of part a) according to the method of Example 3, part d).

c) (R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (isobutyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared from the product of part a) and (R) -4-isoxazolidinol hydrochloride [Example 2b) according to the method of Example 3, part d).

Example 14 iii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl) -1H-pyrrolo [2,3-b] pyridine-3- Yl) methyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 3-methyl-6-[(2-methyl-1H-pyrrolo [2,3-b] pyridin-3-yl) methyl] 2,4-dioxo-1-propyl-1,2,3 , 4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared using the method of Example 6, part b) from Example 9, product of part c) and 2-methyl-1H-pyrrolo [2,3-b] pyridine.

b) sodium 3-methyl-6-[(2-methyl-1H-pyrrolo [2,3-b] pyridin-3-yl) methyl] -2,4-dioxo-1-propyl-1,2, 3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylate

The title compound was prepared from the product of step a) using the method of Example 1, part f).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl) -1H-pyrrolo [2,3-d] pyridine- 3-yl) methyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The product of part b) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b)] were prepared following the procedure of Example 1, part g) to afford the title compound as a solid.

Example 15 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridine-3 -Ylmethyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridin-3-ylmethyl] -2,4- Dioxo-1-propyl-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 13 The title compound was prepared using the product of Example 9, part c) according to the method of xii), part a).

b) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridin-3-ylmethyl] -2,4- Dioxo-1-propyl-thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridine -3-ylmethyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part b) using the procedure described in Example 3, part e).

Example 15 ii)

(S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1-propyl-6- [4,5-dichloro-2-methyl-1H-imidazole-1- Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1- Propyl-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 9, part c) using the procedure described in Example 3, part c).

b) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1- Propyl-thieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of Example, part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1-propyl-6- [4,5-dichloro-2-methyl-1H-imidazole- 1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of Example, part b) using the procedure described in Example 3, part e).

Example 15 iii)

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -Propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-2,4-dioxo-1-propyl -Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Sodium hydride (60 mg, 60% suspension) was added to 2-benzimidazolmethanol (210 mg) in dry DMF at 0 ° C. under nitrogen. After 10 minutes, the product of Example 9c (500 mg) in DMF was added dropwise and the reaction mixture was stirred at room temperature for 3 hours. Water was added and the precipitate obtained by filtration was washed with ethyl acetate and then with ether to give the title compound as a yellow solid (230 mg). The filtrate was extracted twice with dichloromethane. The organics were dried over magnesium sulfate and concentrated in vacuo to afford a brown solid, which was combined with the product obtained earlier to give the title compound as a light brown solid (480 mg).

b) sodium 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-2,4-dioxo-1- Propyl-thieno [2,3-d] pyrimidine-5-carboxylate

Example 15 iii) The title compound was obtained as a white solid (260 mg) using the method of Example 1, part f) from the product of part a) (420 mg).

c) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 15 iii) prepared from the product of part b) using the method of example 13 vii), part c). The crude material was eluted with 25% to 95% acetonitrile in 0.1% aqueous ammonium acetate solution and purified by reverse phase preparative HPLC to give the title compound (75 mg).

Example 15 iv) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- [2-amino-1H-benzimidazole-1- Ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [2-amino-1 H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-thieno [ 2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Sodium hydride (60 mg, 60% suspension) was added to 2-aminobenzimidazole (200 mg) in anhydrous DMF under nitrogen. After 10 minutes, the product of Example 9c (500 mg) in dry DMF was added dropwise and the reaction mixture was stirred at room temperature for 3 hours. Water was added and the precipitate obtained by filtration was washed with ethyl acetate and then with ether to give the title compound as orange-brown crystals (220 mg).

b) 6- [2-amino-1 H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-1-propyl-thieno [ 2,3-d] pyrimidine-5-carboxylic acid

Example 15 iv) The title compound was obtained as a pale yellow solid (190 mg) from the product of part a) (220 mg) according to the method of Example 1, part f).

c) 5-[(4S-4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- [2-amino-1H-benzimidazol-1-ylmethyl-thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 15 iv) from the product of part b) (190 mg) was prepared according to the method of example 13 vii), part c). The crude material was eluted with 5% to 95% acetonitrile in 0.1% aqueous ammonium acetate solution and purified by reverse phase preparative HPLC, then triturated with methanol to give the title compound as a white solid (19 mg).

Example 16 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (Isopropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (isopropyl) -2,4- Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 13 The title compound was obtained after trituration and filtration with ethyl acetate from the product of Example 8, part c) and 2-methylaminobenzimidazole using the procedure described in vii), part a).

b) 1,2,3,4-tetrahydro-3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (isopropyl) -2,4- Dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl]- 1- (isopropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 13 vii) from the product of part b) using the procedure described in part c), eluting with 0% to 3% methanol in dichloromethane, purifying by flash silica chromatography and then triturating with ether to give the title compound Obtained.

Example 16 ii)

(S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl-3-methyl-1 -(Isopropyl) thieno [2,3-d] pyrimidine-5-carboxamide

a) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1,2,3-4-tetrahydro-3-methyl-1- (isopropyl) -2, 4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 8, part c) using the procedure described in Example 3, part c).

b) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1,2,3-4-tetrahydro-3-methyl-1- (isopropyl) -2, 4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of Example, part a) using the procedure described in Example 3, part d).

c) (S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl-3-methyl -1- (isopropyl) thieno [2,3-d] pyrimidine-5-carboxamide

The title compound was prepared from the product of part b) using the procedure described in Example 3, part e).

Example 16 iii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(Isopropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1- (isopropyl) -2,4 -Dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Sodium hydride (79 mg, 60% suspension) was added to 2-benzimidazolmethanol (280 mg) in dry DMF at 0 ° C. under nitrogen. After 10 minutes, the product of Example 8b (660 mg) in DMF was added dropwise and the reaction mixture was stirred at room temperature for 3 hours. Water was added and the precipitate obtained by filtration was washed with ethyl acetate and then with ether to give the title compound as an off white solid (350 mg).

b) sodium 1,2,3,4-tetrahydro-6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl-3-methyl] -1- (isopropyl) -2, 4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

Example 16 iii) The title compound was obtained as a white solid (340 mg) using the method of Example 1, part f) from the product of part a) (350 mg).

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl -1- (isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 16 iii) prepared from the product of part b) using the method of example 13 vii), part c). The crude material was eluted with 25% to 95% acetonitrile in 0.1% aqueous ammonium acetate solution and purified by reverse phase preparative HPLC to give the title compound (110 mg).

Example 16 iv)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-amino-1H-benzimidazol-1-ylmethyl ] Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [2-amino-1 H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo- Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepared according to the method of Example 13 vii), part a) from Example 8b (660 mg) of product and 2-aminobenzimidazole (250 mg). The crude material was purified by flash silica chromatography, eluting with 50% ethyl acetate in isohexane, then 4% methanol in dichloromethane containing 0.1% triethylamine to give the title compound as a yellow foam (360 mg).

b) sodium 6- [2-amino-1 H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo -Thieno [2,3-d] pyrimidine-5-carboxylate

Example 16 iv), from the product of part a) (360 mg), the title compound was obtained as a white solid (190 mg) according to the method of Example 1, part f).

MS (ES) 414 [M + H] ⁺

c) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-amino-1H-benzimidazole-1- Ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 16 iv) from the product of part b) (190 mg) was prepared according to the method of example 13 vii), part c). The crude material was eluted with 25% to 95% acetonitrile in 0.1% aqueous ammonium acetate solution and purified by reverse phase preparative HPLC, then triturated with methanol to give the title compound as a white solid (20 mg).

Example 16 v)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-1-ylmethyl]- 2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

To a stirred suspension of 60% sodium hydride (0.15 g) in THF (5 ml) at ambient temperature under nitrogen was added dropwise a solution of 2-methylazaindole (0.25 g) in THF (5 ml). After stirring for 5 minutes, it was cooled to 0 ° C. and a solution of the product of Example 22, part a) (0.60 g) in THF (10 ml) was added and the mixture was allowed to warm to room temperature and stirred for 5 hours. It was quenched with water, acidified with 2.5 M HCl and extracted with dichloromethane, the organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with ethyl acetate / i-hexane (1: 1), then ethyl acetate / methanol (9: 1) to give the title compound as a solid (0.06 g).

b) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3 -b] pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a solid according to the procedure of Example 1, part g) from the product of part a) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b).

Example 17 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [3,5-diethyl-1H-pyrazole-4- Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [3,5-diethyl-1H-pyrazol-4-ylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetra Hydrothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was obtained as a solid (0.37 g) from the product of Example 3, part c) (3 g) and 3,5-heptanedione using the procedure described in Example 12, part a).

b) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [3,5-diethyl-1 H-pyrazole- 4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a solid from the product of part a) and (S) -4-hydroxyisoxazolidine hydrochloride {Example 1, part b)} using the procedure described in Example 3, part e) ( 145 mg).

Example 17 ii)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [3- (1,1-dimethylethyl) -5-methyl -1H-pyrazol-4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was obtained as a solid from the product of Example 12, part a), 5,5-dimethylhexane-2,4-dione and 35% aqueous hydrazine solution using the procedure described in Example 12, part b).

Example 18 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2-methyl-4-quinolinylmethyl] thieno [ 2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) N-methoxy-N, 2-dimethyl-4-quinolinecarboxamide

Oxalyl chloride (4.5 ml) was added to a solution of 2-methyl-4-quinolinecarboxylic acid (8.2 g) in dichloromethane (100 ml) containing DMF (1 drop). This mixture was heated to reflux for 1 hour. After vacuum drying to dryness, the residue is redissolved in dichloromethane (50 ml), triethylamine (17 ml) is added followed by N, O-dimethylhydroxylamine (8.2 g) and the reaction is brought to ambient temperature. Stirred for 16 h. The reaction mixture was washed with water (2 x 100 ml), the organic solution was evaporated and the residue was eluted with ethyl acetate and purified by chromatography to give the title compound as a brown oil (10 g).

b) 2-methyl-4-quinolinecarboxaldehyde

A 2.5 N diisobutyl ammonium hydride solution in toluene (5.6 ml) was added to a solution of the product of step a) (1.6 g) in dry toluene (40 ml) at −78 ° C. After 2 hours, the reaction was quenched by addition of sodium potassium tartrate (5 g) in water (25 ml) and warmed to room temperature. The organic phase was collected, washed with water, dried over magnesium sulfate and concentrated in vacuo to dryness. The residue was purified by chromatography, eluting with 30% ethyl acetate in i-hexane (0.82 g).

c) 1,1-dimethylethyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxothieno [2,3-d] pyrimidine-5- Carboxylate

Oxalyl chloride (1.0 ml) was added to a solution of the product of Example 1, part c) (2.0 g) in dichloromethane (12 ml) containing DMF (1 drop). The mixture was stirred at rt for 1 h. After concentration in vacuo to dryness, the residue was redissolved in dichloromethane (8 ml), triethylamine (4 ml) was added followed by the addition of 2-methylpropan-2-ol (8.0 ml) and the reaction at ambient temperature. Stir for 4 hours. The reaction mixture was washed with water (2 × 100 ml), the organic phase was dried and evaporated and the residue was eluted with i-hexane / ethyl acetate (5: 1) and purified by chromatography to give the title compound as an orange oil ( 1.6 g).

d) 1,1-dimethylethyl 1,2,3,4-tetrahydro-6- [hydroxy (2-methyl-4-quinolinyl) methyl] -3-methyl] -1- (isobutyl)- 2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

Example 1 A title compound was prepared using the products of steps c) and b) according to the method of step d).

e) 1,1-dimethylethyl 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6-[(2-methyl-4-quinolinyl) methyl] -2,4 -Dioxothieno [2,3-d] pyrimidine-5-carboxylate

Methane sulfonyl chloride (0.46 ml) was added to a solution of the product of step d) (1.42 g) and triethylamine (1.54 ml) in dry THF (30 ml) under nitrogen at room temperature and the mixture was stirred for 40 minutes. . Palladium on 10% charcoal (320 mg) was added and the mixture was hydrogenated at 5 bar for 2 hours. The suspension was washed with methanol (100 ml) and filtered through celite. The organics were concentrated under reduced pressure and the residue was eluted with 1: 3 ethyl acetate / i-hexane and purified by column chromatography to give the title compound as a solid (1.0 g).

f) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2-methyl-4-quinolinylmethyl] -2,4-dioxothieno [2, 3-d] pyrimidine-5-carboxylic acid

To a solution of the product of step e) (0.82 g) in dichloromethane (15 ml) under nitrogen was added trifluoroacetic acid (3 ml) and the mixture was stirred for 1 hour. Saturated sodium bicarbonate solution (100 ml) was added and the mixture was extracted into dichloromethane, the organic phase was washed with water (200 ml), dried over magnesium sulfate, filtered and concentrated to dryness to afford the title compound as a red solid. (0.72 g).

g) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2-methyl-4-quinolinylmethyl] thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared using the products of part f) and example 1, part b) according to the method of Example 1, step g).

Example 18 ii)

(S) -6- [6-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [6-fluoro-4-quinolinyl (hydroxy) methyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydro Thieno [2,3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of Example 1, part c) and 6-fluoro-4-quinolinecarbaldehyde using the procedure described in Example 1, part d).

b) 6- [6-fluoro-4-quinolinylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2 , 3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of part a) using the procedure described in Example 1, part e).

c) 6- [6-fluoro-4-quinolinylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2 , 3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of part b) using the procedure described in Example 1, part f).

d) (S) -6- [6-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) Thieno [2,3-d] pyrimidine-2,4- (1H, 3H) -dione

The title compound was prepared from the product of part c) and (S) -4-hydroxyisoxazolidine hydrochloride {Example 1, part b)} using the procedure described in Example 1, part g).

( ^* Mixture of NB rotamers, no minor rotamomer peaks shown, spectra simplified at high temperatures)

Example 18 iii)

(S) -6- [8-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [8-fluoro-4-quinolinyl (hydroxy) methyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydro Thieno [2,3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of Example 1, part c) and 8-fluoro-4-quinolinecarbaldehyde using the procedure described in Example 1, part d).

b) 6- [8-fluoro-4-quinolinylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2 , 3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of part a) using the procedure described in Example 1, part e).

c) 6- [8-fluoro-4-quinolinylmethyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2 , 3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of part b) using the procedure described in Example 1, part f).

d) (S) -6- [8-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part c) and (S) -4-hydroxyisoxazolidine hydrochloride {Example 1, part b)} using the procedure described in Example 1, part e).

Example 18 iv)

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- (5-quinolinylmethyl) thieno [2,3- d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [hydroxy (5-quinolinyl) methyl] -3-methyl-1- (isobutyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2, 3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of Example 1, part c) and 5-quinolinecarbaldehyde using the procedure described in Example 1, part d).

MS (ESI) 468 [M + H] ⁺ .

b) 3-methyl-1- (isobutyl) -2,4-dioxo-6- (5-quinolinylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] Pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of part a) using the procedure described in Example 1, part e).

c) 3-methyl-1- (isobutyl) -2,4-dioxo-6- (5-quinolinylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] Pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of part b) using the procedure described in Example 1, part f).

d) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isobutyl) -6- (5-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the products of Part c) and Example 1, Part b) using the procedure described in Example 1, part g).

Example 19

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1-propyl-6- (quinolin-4-ylmethyl) thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione

a) 6-chloro-3-methyl-1-propylpyrimidine-2,4 (1H, 3H) -dione

6-Chloro-3-methyl uracil (10 g) and potassium carbonate (10.34 g) in DMF (70 ml) were treated with n-propyl iodide (25.4 g) under nitrogen and heated to reflux for 8 hours. The reaction was cooled and then poured into water (700 ml) and extracted with ethyl acetate. The combined organics were dried and evaporated in vacuo to afford the title compound as an orange oil (17.52 g).

b) 3-methyl-1-propyl-6-mercaptopyrimidine-2,4 (1H, 3H) -dione

The product of step a) (11.43 g) in ethanol (400 ml) was treated with NaSH (6.31 g) under nitrogen. After stirring for 48 hours at room temperature, the solvent was evaporated in vacuo and the residue diluted with water. The aqueous phase was washed with ethyl acetate and then acidified with 2 M HCl. Then it was extracted with ethyl acetate and the combined organics were dried in vacuo and evaporated to give the title compound as an orange oil (7 g).

c) ethyl-3-methyl-2,4-dioxo-1-propyl-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylate

The product of step b) (6.95 g) in dry dimethylformamide (100 ml) was added to potassium carbonate (2.4 g) and stirred for 10 minutes. Ethyl bromopyruvate (5 ml) was added and stirred at room temperature under nitrogen for 2 hours. The reaction was poured into water (1 L), acidified (2 M HCl) and extracted with ethyl acetate. The organic extract was washed with brine (100 ml). Drying and evaporation gave an oil. The oil was dissolved in dichloromethane (100 ml) and ice-cooled with stirring. Titanium tetrachloride (7.58 ml) was added and stirring continued for 2 hours under nitrogen. The reaction was poured into water (1 L) and extracted with dichloromethane. The organics were dried in vacuo and evaporated. The residue was purified by chromatography (SiO ₂ / ethyl acetate-dichloromethane 0% to 8%) to give the title compound as an orange oil (4.64 g).

d) ethyl 6- [hydroxy (quinolin-4-yl) methyl] -3-methyl-2,4-dioxo-1-propyl-1,2,3,4-tetrahydrothieno [2,3- d] pyrimidine-5-carboxylate

The title compound was prepared using the product of step c) using the method of Example 1, part d).

e) ethyl 3-methyl-2,4-dioxo-1-propyl-6- (quinolin-4-ylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine -5-carboxylate

The title compound was prepared using the product of step d) using the method of example 1).

f) sodium 3-methyl-2,4-dioxo-1-propyl-6- (quinolin-4-ylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine -5-carboxylate

The title compound was prepared using the product of step e) following the method of Example 1, part f).

g) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1-propyl-6- (quinolin-4-ylmethyl) thieno [2,3-d ] Pyrimidine-2,4 (1H, 3H) -dione

Prepared using the product of step f) and (S) -isoxazolidin-4-ol hydrochloride according to the method of Example 1, part g).

Example 20

(S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isopropyl) -6- (4-quinolinylmethyl) thieno [2,3- d] pyrimidine-2,4 (1H, 3H) -dione

a) diethyl 2-((isopropyl) amino) thiophene-3,4-dicarboxylate

Ethoxycarbonylmethylene triphenyl phosphoran (33.8 g) in dry THF (200 ml) was treated with isopropyl isothiocyanate (10.1 g) under nitrogen at 65 ° C. for 16 hours. The mixture was cooled to -78 ° C and ethyl bromo-pyruvate (19.5 g) was added. The reaction was slowly warmed to room temperature. After 24 hours more ethyl bromopyruvate (3.17 g) was added at room temperature and the mixture was stirred at room temperature for 16 hours. The reaction was poured into water (1.5 L) and extracted into ether. Was by - (ethyl acetate 1 isohexane SiO _2/5) to give the title compound (21.2 g) was dried and evaporated to give an oil which this chromatography.

b) ethyl 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

Silver cyanate (4.5 g) suspended in anhydrous toluene (30 ml) was treated dropwise with acetyl chloride (1.78 ml) under nitrogen and stirred vigorously for 30 minutes. The product of step a) (7.12 g) dissolved in anhydrous toluene (5 ml) was added and the mixture was stirred for 24 hours. Ether (120 ml) was added and the insoluble material was filtered off and washed with a small volume of ether. The combined organic solutions were washed with saturated sodium bicarbonate solution, dried and evaporated. The residue was treated with a solution of sodium ethoxide (prepared from 1.95 g of sodium and 35 ml of ethanol) in ethanol for 24 hours at room temperature. The reaction was ice cooled, treated with trimethylsilyl chloride (20 ml) and stirred overnight at room temperature. All volatiles were removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic solution was dried and evaporated to give a residue. It was treated with potassium carbonate (6.95 g) and methyl iodide (8.5 g) in dry DMF (50 ml) at room temperature for 24 hours. The mixture was poured into water (1 L), acidified and extracted into ether. Wash with brine, dry and evaporate to give an oil. Chromatography: - by (SiO _2/3 1 isohexane-ethyl acetate) to give the title compound (3.1 g).

c) 6- [hydroxy (4-quinolinyl) methyl] -3-methyl-1- (isopropyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2, 3-d] pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of part b) and 4-quinolinecarbaldehyde using the procedure described in Example 1, part d).

d) 3-methyl-1- (isopropyl) -2,4-dioxo-6- (4-quinolinylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] Pyrimidine-5-carboxylic acid, ethyl ester

The title compound was prepared from the product of part c) using the procedure described in Example 1, part c).

e) 3-methyl-1- (isopropyl) -2,4-dioxo-6- (4-quinolinylmethyl) -1,2,3,4-tetrahydrothieno [2,3-d] Pyrimidine-5-carboxylic acid, sodium salt

The title compound was prepared from the product of part d) using the procedure described in Example 1, part f).

f) (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (isopropyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared from the product of part e) using the procedure described in Example 1, part g).

( ^* 1: 1 mixture of NB major rotamers, no minor isomer peaks shown)

Example 21 i)

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(2-methyl-1H-pyrrolo [2,3- b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepared using the product of Example 3, part b) and 2-methyl-7-azaindole according to the method of Example 6, part a).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-yl Methyl) thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared from the product of part a) according to the method of Example 3, step d) (1.22 g).

c) (S) -5-[[4-hydroxyisoxazolidin-2-yl] carbonyl] -3-methyl-1- (isobutyl) -6-[(2-methyl-1H-pyrrolo [ 2,3-b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound was prepared according to the method of Example 1, step g) from the product of step b).

Example 21 ii)

(R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6-[(2-methyl-1H-pyrrolo [2,3- b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Preparation of the title compound using (R) -4-hydroxyisoxazolidine (Example 2, part b)) according to the method of Example 1, step g) from the product of Example 21 i), step b) It was.

Example 22

(S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 6- (bromomethyl) -1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxothieno [2,3-d] pyrimidine -5-carboxylate

A solution of the product of Example 8, part b) (1.6 g), N-bromosuccinimide (1 g) and azoisobutyronitrile (10 mg) in ethyl acetate (25 ml) was refluxed for 1 hour. . The solution was cooled to room temperature, washed sequentially with dilute sodium hydroxide solution and water, and the organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with diethyl ether / i-hexane (1: 1) to afford the title compound as a solid (1.5 g).

b) methyl 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-3-ylmethyl] -2,4-dioxothieno [2,3-d] pyrimidine-5-carboxylate

To a stirred suspension of 60% sodium hydride (0.23 g) in THF (10 ml) at ambient temperature under nitrogen was added dropwise a solution of 2-methylazaindole (0.37 g) in THF (10 ml), and after 5 minutes, ether (5.6 1 M zinc chloride in ml) was added. After stirring for 5 minutes, a solution of the product of part a) (0.88 g) in THF (10 ml) was added and the mixture was stirred for 3 hours. It was quenched with water and extracted with ethyl acetate, and the organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with ethyl acetate / i-hexane (1: 1) to afford the title compound as a solid (0.4 g).

c) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-3ylmethyl] -2 , 4-dioxothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was obtained as a solid from the product of part b) following the procedure of Example 1, part f).

d) (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3 -b] pyridin-3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a solid according to the procedure of Example 1, part g) from the product of part c) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b).

Example 23

(S) -6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl]- 3-Methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4- (1H, 3H) -dione

a) 4,5-dichloro-1H-imidazole-2-methanol

Potassium hydroxide (0.12 g, 2.14 mmol) in water (4 ml) was added to 4,5-dichloromethane and the suspension was stirred for 35 minutes. Paraformaldehyde (O.11 g, 3.66 mmol) was partially added and the reaction mixture was stirred overnight, acidified with dilute HCl to pH 1 and concentrated in vacuo to afford a white solid (0.6 g, 98%).

b) 6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl ) -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Potassium carbonate (0.14 g, 3.1 mmol) and product of part a) (0.51 g, 3.09 mmol) were added to a solution of the product of Example 3, part b) in DMF, and the reaction mixture was stirred for 16 hours. The solid precipitate formed was filtered off and the filtrate was concentrated in vacuo to give an orange solid (0.6 g, containing DMF).

c) 6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl ) -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

Prepared according to the procedure of Example 3, step d) from the product of step b).

MS (ESI) 484 [M + H] ⁺

d) 6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl ] -3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the process of Example 3, part e) from the product of step c). The product was eluted with ammonium acetate: acetonitrile (70:30) and purified by reverse phase preparative HPLC to afford the title compound as a white solid.

Example 24

(S) -6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (iso Butyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo -Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 3, part b) product (0.4 g, 1.03 mmol), 2,4-dimethylpyrazole (0.2 g, 2.06 mmol) and dimethyl acetamide (approximately 0.5 ml) in a microwave oven at 100 ° C. for 5 minutes. Heated. The reaction mixture was concentrated in vacuo and then softened to yield 0.34 g (84%).

b) 6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo -Thieno [2,3-d] pyrimidine-5-carboxylic acid

Prepared according to the procedure of Example 3, step d) from the product of step a).

MS (ESI) 391 [M + H] ⁺

c) 6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (Isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the procedure of Example 3, part e) from the product of step b). The product was eluted with ammonium acetate: acetonitrile (70:30) and purified by reverse phase HPLC to afford the title compound as a white solid.

Example 25

(S) -6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3- Methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl)- 2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 3, part b) product (0.5 g, 1.28 mmol), 2-chlorobenzimidazole (0.21 g, 1.37 mmol), potassium carbonate (0.36 g, 2.6 mmol) and DMF (10 ml) for 1.5 h Stirred. Ethyl acetate and water were added to the reaction mixture. The two phases were separated and the organic layer was dried (MgSO ₄ ) and concentrated in vacuo. The residue was eluted with dichloromethane and purified by Biotage to afford the title compound as a pale yellow solid (0.36 g, 61%).

b) 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl)- 2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

The product of step a) (0.36 g, 0.65 mmol) was added to a solution of THF (10 ml), water (1 ml) and triethylamine (0.05 ml) in a sealed tube, which was heated at 180 ° C for 3 days. . The reaction mixture was concentrated in vacuo to afford the title compound (0.3 g of crude product).

c) 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl]- 3-methyl-1- (isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the procedure of Example 3, part e) from the product of step b). The product was eluted with ammonium acetate: acetonitrile (80:20) and purified by reverse phase HPLC to triturate with diethyl ether to afford the title compound as a pale yellow foam.

Example 26

(S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propylthier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-methyl-2,4-dioxo-1-propyl-1,2,3,4-tetrahydrothieno [ 2,3-d] pyrimidine-5-carboxylic acid, sodium salt

Zinc bis (acetylacetonate) (0.405 g) was added to a solution of the product of Example 9, part c) (0.56 g) in chloroform (15 ml) and the resulting suspension was stirred at reflux for 15 minutes, then to room temperature Cooled. Saturated sodium bicarbonate solution (10 ml) was added and the mixture was vigorously stirred for 5 minutes, then filtered and extracted with dichloromethane (2 x 25 ml). The combined organic extracts were treated with aqueous hydrazine solution (35%, 0.26 ml), stirred for 16 hours, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (15 ml) and methanol (3.1 ml) then treated with sodium hydroxide solution (1 M, 2.16 ml) and the mixture was stirred for 18 hours. The resulting precipitate was collected by filtration, washed with tetrahydrofuran and dried in vacuo to give the title compound (0.42 g).

b) (S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl-3-methyl-1-propyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a solid according to the procedure of Example 1, part g) from the product of part a) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b).

( ^* NB material is present as a mixture of rotamers, so NMR is complex at room temperature but simplified at elevated temperature)

Example 26 i)

(S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isopropyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -1-isopropyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was obtained as a solid from the product of Example 8, part b) following the procedure of Example 26, part a).

b) (S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isopropyl-3 -Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a solid according to the procedure of Example 1, part g) from the product of part a) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b).

Example 27

(S) -6- [3,5-dimethylisoxazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 6- [3,5-dimethylisoxazol-4-ylmethyl] -1- (isobutyl) -3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothier No [2,3-d] pyrimidine-5-carboxylate

Zinc bis (acetylacetonate) (0.724 g) was added to a solution of the product of Example 3, part b) (1.O g) in chloroform (20 ml) and the resulting suspension was stirred at reflux for 30 minutes and then at room temperature Cooled to. Saturated sodium bicarbonate solution (20 ml) was added and the mixture was vigorously stirred for 5 minutes, filtered and then extracted with dichloromethane (2 x 20 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was dissolved in ethanol (10 ml), hydroxylamine hydrochloride (0.54 g) and pyridine (0.62 ml) were added and the mixture was stirred for 16 hours. Hydrochloric acid (2 M, 5 ml) was added and stirring continued for 24 hours. After the mixture was evaporated to low volume, saturated sodium bicarbonate solution (25 ml) was added and extracted with ethyl acetate (2 × 25 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica eluting with ethyl acetate / iso-hexane (2: 1) and the product was triturated with ether to give the title compound (0.55 g).

b) 6- [3,5-dimethylisoxazol-4-ylmethyl] -1- (isobutyl) -3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was obtained as a solid from the product of part a) following the procedure of Example 3, part d).

c) 6- [3,5-dimethylisoxazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-yl carbonyl] -1- (isobutyl) -3 -Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The title compound is obtained as a foam according to the procedure of Example 1, part g) from the product of part b) and (S) -4-isoxazolidinol hydrochloride [Example 1, part b)].

Example 28

6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl]- 3-methyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1-ethyl-3,6-dimethyl-2,4 (1H, 3H) -pyrimidinedione

Potassium carbonate (2.1 g) was added to a suspension of 3,6-dimethyl-2,4 (1H, 3H) -pyrimidinedione (2.0 g) in DMF (15 ml) at room temperature. The mixture was stirred for 5 minutes, then ethyl iodide (1.2 ml) was added and the mixture was stirred for 3 days. The reaction mixture was partitioned between water (500 ml) and ethyl acetate (3 x 100 ml). The combined organic phases were dried (MgSO ₄ ) and evaporated to give the title compound as a colorless oil (2.0 g) (containing 30 mol% DMF, confirmed by NMR).

b) 1-ethyl-6-mercapto-3-methyl-2,4 (1H, 3H) -pyrimidinedione

Prepared according to the procedure of Example 5, step a) from the product of step a).

c) methyl 1-ethyl-1,2,3,4-tetrahydro-3,6-dimethyl-2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

Prepared according to the procedure of Example 3, step a) from the product of step b).

d) methyl 6- (bromomethyl) -1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-thieno [2,3-d] pyrimidine-5 Carboxylate

Prepared according to the procedure of Example 22, step a) from the product of step c).

e) methyl 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4- Dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

The mixture of product of step d) (0.25 g), sodium bicarbonate (0.29 g) and 4,5-dichloro-2-methyl-1H-imidazole (0.115 g) in acetonitrile (10 ml) was heated to reflux for 18 hours. It was. The cooled mixture was partitioned between water (50 ml) and dichloromethane (3 x 50 ml). The combined organic phases were dried (MgSO ₄ ) and evaporated to afford the title compound as an oil, which was used directly in the next step.

f) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-di Oxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

Prepared according to the procedure of Example 1, step f) from the product of step e).

g) 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl ] -3-methyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 1, step g) using the amine of Example 1, step b) from the product of step f).

( ^* NB material is present as a mixture of rotamers, so NMR is complex at room temperature but simplified at elevated temperature)

Example 28 i)

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl ) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl) thier No [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared from the product of Example 28, part d) according to the method of Example 22, part b.

b) 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl) thier No [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared according to the method of Example 3, part d).

MS (ESI) 386 [M + H] ⁺

c) 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- (1H-pyrrolo [2,3-b] pyridine-3- Ylmethyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the procedure of Example 3, part e) from the product of step b). The product was eluted with ammonium acetate: acetonitrile (70:30) and purified by reverse phase HPLC to afford the title compound as off-white solid.

Example 28ii)

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -thieno [2,3-d] pyrimidine-5-carboxylate

Prepared according to the procedure of Example 13 iv), step a) from the product of Example 28, step d).

b) 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -thieno [ 2,3-d] pyrimidine-5-carboxylic acid, sodium salt

Prepared according to the procedure of Example 1, step f) from the product of step a).

MS (ESI) 427 [M + H] ⁺ (Free Acid)

c) 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 1, step g) using the amine of Example 1, step b) from the product of step b).

Example 28 iii)

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-oxo-3 (2H) -benzothiazolylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- [2-oxo-3 (2H) -benzothiazolylmethyl] -thieno [ 2,3-d] pyrimidine-5-carboxylate

Example 28 Prepared from the product of step d) following the procedure of example 13 xviii), step a).

b) 1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-6- [2-oxo-3 (2H) -benzothiazolylmethyl] -thieno [2 , 3-d] pyrimidine-5-carboxylic acid, sodium salt

Prepared according to the procedure of Example 1, step f) from the product of step a).

MS (ESI) 418 [M + H] ⁺ (free acid)

c) 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-oxo-3 (2H) -benzothiazolylmethyl] thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 1, step g) using the amine of Example 1, step b) from the product of step b).

Example 28 iv)

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] pyridine- 3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) methyl 1-ethyl-1,2,3,4-tetrahydro-3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-3-ylmethyl] -2, 4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

Prepared according to the procedure of Example 14 iii), step a) from the product of Example 28, step d).

b) 1-ethyl-1,2,3,4-tetrahydro-3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] pyridin-3-ylmethyl] -2,4 -Dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

Prepared according to the procedure of Example 1, step f) from the product of step a). This was used directly in the next step.

c) 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] Pyridin-3-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 1, step g) using the amine of Example 1, step b) from the product of step b).

Example 28 v)

1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [5-cyano-1H-indol-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [5-cyano-1H-indol-1-ylmethyl] -1-ethyl-1,2,3,4-tetrahydro-3-methyl-2,4-dioxo-thieno [2 , 3-d] pyrimidine-5-carboxylic acid, methyl ester

Prepared according to the method of Example 13 xvii), part a) using the product of Example 28, part d).

b) 1- [1-ethyl-1,2,3,4-tetrahydro-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-2,4- Dioxothieno [2,3-d] pyrimidin-6-ylmethyl] -1H-indole-5-carbonitrile

The title compound was prepared according to the method of Example 13 xvii), part b) and part c) using the product of part a).

Example 29 i)

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -6- [1-isopropyl-3,5-dimethyl-1H-pyrazole-4- Ylmethyl] -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

2-iodopropane (0.1 ml) and potassium carbonate (100 mg) were added to 6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -5 in dimethylformamide (1 ml). -[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H ) -Dione (Example 11, 100 mg) was added and the mixture was stirred at 100 ° C. After 2 hours, further 2-iodopropane (0.2 ml) and potassium carbonate (200 mg) were added. After 16 h, the mixture was cooled to rt, diluted with water (20 ml) and extracted with ethyl acetate (2 × 20 ml). The combined organic extracts were treated with pyrrolidine (0.1 ml), dried after an hour with anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by reverse phase HPLC eluting with 0.1% aqueous ammonium acetate / acetonitrile to afford the title compound as a foam (58 mg).

Example 29 ii)

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl-6- [5-methyl-3-phenyl-1H-pyrazole-4 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 1-isobutyl-3-methyl-6- [5-methyl-3-phenyl-1H-pyrazol-4-ylmethyl] -2,4-dioxo-1,2,3,4-tetra Hydrothieno [2,3-d] pyrimidine-5-carboxylate

Zinc (II) acetate (88 mg) was dissolved in methyl 6- (bromomethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetra in chloroform (10 ml). To a stirred solution of hydrothieno [2,3-d] pyrimidine-5-carboxylate (185 mg) and 1-benzoylacetone (154 mg), the mixture was heated to reflux for 1 hour and then cooled to room temperature I was. Saturated sodium bicarbonate solution (20 ml) was added and the mixture was stirred for 30 minutes, then filtered and phase separated. The aqueous phase was extracted with dichloromethane (10 ml). The combined organic extracts were treated with hydrazine hydrate (0.046 ml) and methanol. After 20 hours, this solution was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the title compound (300 mg) mixed with 5-methyl-3-phenyl-1H-pyrazole.

b) 1-isobutyl-3-methyl-6- [5-methyl-3-phenyl-1H-pyrazol-4-ylmethyl] -2,4-dioxo-1,2,3,4-tetrahydro Thieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide solution (1 M, 0.58 ml) was added to a stirred solution of the product of part a) (300 mg) in tetrahydrofuran (10 ml) and methanol (1 ml). After 48 h, water (20 ml) was added and the mixture was extracted with ether (20 ml). Hydrochloric acid (2 M) was added to acidify the aqueous phase to pH 5 and extracted with ethyl acetate (2 x 20 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the title compound as a solid (205 mg).

c) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-3-methyl-6- [5-methyl-3-phenyl-1H-pyrazole-4 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Diethyl Chloridophosphate (0.076 ml) is a stirred solution of the product of Part b) (200 mg), 1-hydroxybenzotriazole hydrate (81 mg) and triethylamine (0.215 ml) in acetonitrile (2 ml) Was added. After 15 minutes, (S) -4-isoxazolidinol hydrochloride [Example 1, Part b), 61 mg] was added. After 24 hours, the mixture was diluted with saturated aqueous sodium bicarbonate solution (10 ml) and extracted with ethyl acetate (2 x 20 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with ethyl acetate / methanol (25: 1) and then recrystallized from ethyl acetate / iso-hexane to give the title compound (138 mg).

Example 29 iii)

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-3-methyl-6- [5-methyl-3- (trifluoromethyl) -1H-pyra Zol-4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) methyl 1-isobutyl-3-methyl-6- [5-methyl-3- (trifluoromethyl) -1H-pyrazol-4-ylmethyl] -2,4-dioxo-1,2, 3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylate

Methyl 6- (bromomethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-car Prepared according to the procedure of Example 29 (ii), part a) from carboxylate (300 mg) and 1,1,1-trifluoroacetylacetonate. The crude product was purified by column chromatography on silica eluting with ethyl acetate / iso-hexane (2: 3) to give the title compound (130 mg).

b) 1-isobutyl-3-methyl-6- [5-methyl-3- (trifluoromethyl) -1H-pyrazol-4-ylmethyl] -2,4-dioxo-1,2,3 , 4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was obtained as a solid from the product of part a) following the procedure of Example 29 (ii), part b).

c) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-3-methyl-5-methyl-3- (trifluoromethyl) -1H-pyrazole 4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of part b) the title compound was obtained as a solid according to the procedure of Example 29 (ii), part c).

Example 29 iv)

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-6- [3-isopropyl-5-methyl-1H-pyrazol-4-ylmethyl]- 3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1-isobutyl-6- [3-isopropyl-5-methyl-1H-pyrazol-4-ylmethyl] -3-methyl-2,4-dioxo-1,2,3,4-tetra Hydrothieno [2,3-d] pyrimidine-5-carboxylic acid

Methyl 6- (bromomethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-car Ester according to the procedure of Example 29 (iii), part a) from carboxylate (450 mg) and 5-methylhexane-2,4-dione, followed by the procedure of Example 29 (ii), part b) Hydrolysis gave the title compound as a solid (285 mg).

b) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-6- [3-isopropyl-5-methyl-1H-pyrazol-4-ylmethyl ] -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the procedure of Example 29 (ii), part c) from the product of part a) (281 mg). The crude product was gradient eluted with 0.1% aqueous ammonium acetate / acetonitrile and purified by reverse phase HPLC and then triturated with ether to give the title compound as a solid (170 mg).

Example 29 v)

6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4 Tetrahydrothieno [2,3-d] pyrimidine-5-carboxylate

Methyl 6- (bromomethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-car Prepared according to the procedure of Example 26, part a) from carboxylate (500 mg), zinc acetylacetonate hydrate and phenyl hydrazine. The crude product was purified by column chromatography on silica eluting with ethyl acetate / iso-hexane (2: 3) to give the title compound as a solid (555 mg).

b) 6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4- Tetrahydrothieno [2,3-d] pyrimidine-5-carboxylic acid, sodium salt

The title compound was obtained as a solid from the product of part a) following the procedure of Example 1, part f).

c) 6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- Isobutyl-3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of part b) the title compound was obtained as a solid according to the procedure of Example 29 (ii), part c).

Example 29 vi)

6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl- 1-propylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

6- (Bromomethyl) -3-methyl-1-propyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine in chloroform (10 ml) A solution of -5-carboxylic acid (500 mg) and zinc acetylacetonate hydrate (389 mg) was stirred at reflux for 1 hour and then cooled to room temperature. Water (10 ml) and phenyl hydrazine (0.27 ml) were added and the mixture was stirred for 3 days and phase separated. The aqueous phase was extracted with dichloromethane (2 x 10 ml). The organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was dissolved in acetonitrile (5 ml) and treated with 1-hydroxybenzotriazole (173 mg), triethylamine (0.63 ml) and diethyl chloridophosphate (0.22 ml). The mixture was stirred for 1 hour and then (S) -4-isoxazolidinol hydrochloride [Example 1, Part b), 173 mg] was added. After 24 hours, the mixture was evaporated under reduced pressure and the residue was purified by reverse phase HPLC eluting with 0.1% aqueous ammonium acetate / acetonitrile gradient. The product was further purified by column chromatography on silica eluting with ethyl acetate / methanol (49: 1) to give the title compound as a foam (150 mg).

Example 30

6- (1H-1,2,3-benzotriazol-1-ylmethyl) -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl)- Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- (1H-1,2,3-benzotriazol-1-ylmethyl) -1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-di Oxothieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

To a solution of benzotriazole (0.19 g) in dry tetrahydrofuran under nitrogen was added sodium hydride (0.06 g, 60% suspension). After 10 minutes, the product from Example 8, part c) in dry tetrahydrofuran (0.6 g) was added dropwise. The reaction mixture was stirred at rt overnight. Water was added and the reaction mixture was extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate and concentrated in vacuo. The obtained residue was purified by silica chromatography, eluting with 30% in ethyl acetate, then 40% isohexane, to give the title compound as a white foam (0.32 g).

b) 6- (1H-1,2,3-benzotriazol-1-ylmethyl) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo -Thieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide (1.5 ml, 1 M) was added to a solution of the product of Example 30 a) in tetrahydrofuran under nitrogen. Thereafter, about 1 ml of methanol was added to dissolve the reaction mixture. The reaction mixture was stirred at rt for 5 h. Hydrochloric acid (0.7 ml, 2 M) was added and the reaction mixture was dried in vacuo to afford the title compound.

c) 6- (1H-1,2,3-benzotriazol-1-ylmethyl) -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl ) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Hydroxybenzotriazole (0.23 g), (4S) -4-hydroxyisoxazolidine hydrochloride (described in Example 1, part b)) (0.16 g) and triethylamine (0.22 ml) under dichloromethane To a solution of the product of Example 30 b) in methane. After 10 minutes, EDCI (0.29 g) was added. The reaction mixture was stirred overnight at room temperature. Water was added and the reaction mixture was extracted with dichloromethane. The organics were washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was first purified by silica chromatography, eluting with ethyl acetate and then by reverse phase HPLC to give the title compound as a white foam.

Example 31

5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl) -6-[(2-oxothiazolo [5,4-b] pyridine-1 (2H ) -Yl) methyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo-6- [2-oxothiazolo [5,4-b] pyridine-1 ( 2H) -ylmethyl] -thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

[1,3] thiazolo [5,4-b] pyridin-2 (1H) -one (0.24 g) (described in Example 13 xiii), part c) using the procedure described in example 30a) And the product from Example 8, part c) (0.6 g). The residue was triturated with ether and then filtered to afford the title compound.

b) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -2,4-dioxo-6- [2-oxothiazolo [5,4-b] pyridine-1 ( 2H) -ylmethyl] -thieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide (0.78 ml, 1 M) was added to a solution of the product of Example 31, part a) (0.35 g) in tetrahydrofuran under nitrogen. Then 1 ml of methanol was added to dissolve the mixture and the reaction mixture was stirred for 48 hours at room temperature. The precipitate formed was filtered off, washed with tetrahydrofuran and then with ether to give the title compound (0.18 g).

c) 5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-oxothiazolo [5,4-b] pyridine-1 ( 2H) -ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Hydroxybenzotriazole (0.12 g) was added to a suspension of the product of Example 31 b) in tetrahydrofuran under nitrogen. After 10 minutes, EDCI (0.15 g) was added and after another 40 minutes, (4S) -4-hydroxyisoxazolidine hydrochloride (0.06 g) and triethylamine (0.07 ml) were added. The reaction mixture was stirred at rt overnight. Water was added and the mixture was extracted with dichloromethane. The organics were washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica chromatography eluting with 5% methanol in dichloromethane to afford the title compound as a white foam.

Example 32

6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (Isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -6- [2- (methylthio) -1H-benzimidazol-1-ylmethyl] -2,4- Dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

From the product of Example 8, part c) and 2-methylmercaptobenzimidazole using the procedure described in Example 3, part c), eluting with isohexane / ethyl acetate (1/1) and silica chromatography After purification the title compound was obtained as a pale yellow solid.

b) 1,2,3,4-tetrahydro-3-methyl-1- (isopropyl) -6- [2- (methylsulfonyl) -1H-benzimidazol-1-ylmethyl] -2,4 -Dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

mCPBA (1.2 g) was added to a solution of the product of Example 31, part a) (0.64 g) in dichloromethane. The reaction mixture was stirred at rt for 2 h. The reaction mixture was washed with 10% sodium metabisulfite solution (40 ml), sodium hydrogenocarbonate, then brine. The organics were dried over magnesium sulfate and concentrated in vacuo to afford the title compound.

c) 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isopropyl)- 2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydrogenocarbonate (0.55 g) was added to a suspension of the product (0.54 g) from Example 32, part b) in water. The reaction mixture was heated to reflux for 17 hours. The reaction mixture was washed with ethyl acetate and the aqueous layer was lyophilized to give the title compound (0.7 g).

d) 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl- 1- (isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

From the product of Example 32, part c) using the procedure described in Example 31, part c), purified by silica chromatography, eluting with 0% in ethyl acetate and then 1% methanol in 0.1% aqueous ammonium acetate Elution with acetonitrile (95: 5 to 5:95) and purification by reverse phase HPLC gave the title compound.

Example 33

6- [5,6-difluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxy-2-isoxazole Ridinylcarbonyl] -3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 5,6-difluoro-2-mercaptobenzimidazole

A stirred suspension of 3,4-difluoro-6-nitroaniline (2 g) and palladium (100 mg) on 5% charcoal in ethanol (30 ml) was hydrogenated at 5 bar for 24 hours. The mixture was filtered through celite and concentrated in vacuo to afford a solid, which was dissolved in DMF (20 ml) and treated with carbon disulfide (10 ml). This solution was stirred at ambient temperature for 5 hours. This solution was poured into water and the resulting mixture was extracted with ethyl acetate (x3). The combined organic extracts were dried (MgSO ₄ ) and concentrated in vacuo to give a dark red solid (2.45 g).

b) 5,6-difluoro-2- (methylthio) benzimidazole

A stirred suspension of 5,6-difluoro-2-mercaptobenzimidazole (2.4 g) and potassium carbonate (1.78 g) in acetone was treated with methyl iodide (0.8 ml) and stirred for 2 hours. The reaction was evaporated to dryness and the residue suspended in water (300 ml). This mixture was extracted with ethyl acetate (x3). The combined organic extracts were dried (MgSO ₄ ) and evaporated. The residue chromatographed (SiO _2/2: 8 ethyl acetate-isohexane) to give the title compound (1.95 g).

c) 6- [5,6-difluoro-2-oxo-2,3-dihydro-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidine 2-ylcarbonyl] -1-isobutyl-3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

m-CPBA was added to dichloromethane and the reaction mixture was stirred for 1 hour. The reaction mixture was poured into a 10% sodium metabisulfite (160 ml) solution. The two phases were separated and the organics were washed with sodium bicarbonate, brine, then dried (MgSO ₄ ) and concentrated in vacuo to afford a yellow foam. This foam was treated with water (5 ml), THF (5 ml) and sodium bicarbonate (0.37 g). The reaction mixture was stirred at reflux for 48 hours. A precipitate formed which was filtered and washed with water to give a white solid. This solid was treated with THF (7 ml), HOBT (0.2 g) and EDCI (0.28 g). The reaction mixture was stirred at reflux for 35 minutes and then triethylamine (0.24 ml) and (S) -hydroxyisoxizolidine were added. HCl (0.18 g) was added. The reaction mixture was stirred at reflux for 2 days. The residue chromatographed: - by (SiO _{2/98 2} ethyl acetate to methanol) to give a yellow solid. It was recrystallized from methanol to give the title compound as a white crystalline solid (0.18 g).

Example 34

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) Methyl 6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothier No [2,3-d] pyrimidine-5-carboxylate

Example 3, the product of part b (1 g), imidazolo [1,2-a] pyridine (0.4 ml), potassium carbonate (0.35 g) and THF (20 ml) were stirred under nitrogen for 1 hour. Water was added to the reaction and extracted with ethyl acetate (x2). The combined organic extracts were dried (MgSO ₄ ) and concentrated in vacuo. The residue chromatographed: - to provide the title compound (SiO _2/9 1 ethyl acetate-hexane and ethyl acetate) as a colorless oil.

LCMS (ESI) 4275 [M + H] ⁺

b) 6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidine-5-carboxylic acid

The product of part a) was treated with sodium hydroxide (0.75 ml), THF (5 ml) and methanol (0.05 ml) and the resulting solution was stirred under nitrogen for 2 hours. The reaction mixture was washed with ethyl acetate. The aqueous phase was concentrated in vacuo to afford the title compound (0.13 g).

c) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3 -Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Step b) (0.13 g) of the product was dissolved in THF (3 ml). HOBT (0.09 g) was added followed by EDCI (0.12 g). After stirring for 10 minutes triethylamine (0.05 ml) and (S) -hydroxyisoxizolidine were added. HCl (0.08 g) was added and the reaction mixture was stirred for 16 h. Water (10 ml) and ethyl acetate (10 ml) were added. The two phases were separated and the aqueous layer was reextracted with ethyl acetate. The combined organic extracts were dried (MgSO ₄ ) and concentrated in vacuo. The compound was eluted with ammonium acetate: acetonitrile (80:20) and purified by RPHPLC to give the title compound as a white solid.

Example 35

3-methyl-6- [2-methylindol-3-ylmethyl] -1- (isobutyl) -5- (tetrahydroisoxazine-2-ylcarbonyl) -thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione

3-methyl-6- [2-methylindol-3-ylmethyl] -1- (isobutyl) -5- (tetrahydroisoxazine-2-ylcarbonyl) -thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione

The title compound was prepared using the product of Example 5, part b) and tetrahydro-1,2-oxazine hydrochloride according to the method of Example 1, part g).

Example 36

6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2 , 4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Product (1 g) from Example 3, part b) was added to a solution of 2-bromo-4,5-dichloroimidazole (0.73 g) and potassium carbonate (1 g) in anhydrous dimethylformamide. The reaction was stirred at rt for 2 days, then diluted with water and extracted with ethyl acetate (twice). The organics were dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash silica chromatography eluting with 20% ethyl acetate in isohexane to give the title compound (0.84 g).

b) 6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2 , 4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

Sodium hydroxide (2 ml of 1 M aqueous solution), then methanol (0.5 ml) was added to a solution of the product of step a) (0.85 g) in tetrahydrofuran (7 ml) and stirred at room temperature for 2 hours. The precipitate formed was filtered and washed with tetrahydrofuran to give the title compound as a white solid (0.81 g).

c) 6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1 -(Isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

2% in dichloromethane from the product of Example 10 step b) and the product of (4S) -4-hydroxyisoxalidine hydrochloride (Example 1b) using the procedure described in Example 1, part g) Elution with methanol and purification by flash silica chromatography gave the title compound.

Example 37

5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [4, 5-b] pyridin-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 2- (methylthio) -1H-imidazo [4,5-b] pyridine

Potassium ethylxanthate (4.51 g) was added to 2,3-diaminipyridine (2.51 g) in ethanol (25 ml) and water (5 ml). The reaction mixture was refluxed for 24 hours and then cooled. A precipitate formed which was filtered, washed with ethanol and then with ether to give a pale pink solid (3.16 g). Potassium hydroxide (23 ml, 1 M) was added to this solid and after 5 minutes iodomethane (1.3 ml) was added. The reaction mixture was stirred overnight at room temperature and then extracted with ethyl acetate. The aqueous layer was concentrated in vacuo. The residue was triturated with methanol and the insoluble solids were filtered off. After the filtrate was concentrated in vacuo, the residue was triturated with dichloromethane and filtered to give the title compound as a beige solid (440 mg).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [4,5-b] pyridin-1-yl Methyl] -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 3b) Example 13 vii) from (815 mg) of product and 2- (methylthio) -1H-imidazo [4,5-b] pyridine (Example 37, part a)) (342 mg), Prepared according to the method of part a). The crude material was purified by flash silica chromatography eluting with 50% ethyl acetate in isohexane, then 3% methanol in dichloromethane to give the title compound (190 mg) as well as the product of Example 22 i), part a). (40 mg).

c) sodium 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [4,5-b] pyridine-1- Monomethyl] -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylate

Sodium hydroxide (0.8 ml, 1 M) was added to a solution of the product of Example 37, part b) (190 mg) in tetrahydrofuran under nitrogen. Methanol was added to dissolve this solution and the reaction mixture was stirred at room temperature for 3 hours. HCl (0.4 ml, 2 M) was added to neutralize this solution and the mixture was concentrated in vacuo to afford the title compound.

d) 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [ 4,5-b] pyridin-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared according to the method of Example 1, part g) from the product of Example 37, part c). The crude material was eluted with 25% to 95% acetonitrile in 0.1% aqueous ammonium acetate and purified by reverse phase preparative HPLC to give the title compound as a colorless oil (47 mg).

Example 37 i)

5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -3H-imidazo [4,5-b] Pyridin-3-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -3H-imidazo [4,5-b] pyridin-3-yl Methyl] -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Obtained from the reaction of Example 37, part b).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -3H-imidazo [4,5-b] pyridin-3-yl Methyl] -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

The title compound was prepared according to the method of Example 22, part c) from Example 37 i), product of part a) (40 mg).

c) 5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -3Himidazo [4,5-b ] Pyridin-3-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Example 37 i), from the product of part b), were prepared according to the method of example 1, part g). The crude material was purified by flash silica chromatography eluting with 3% methanol in dichloromethane and triturated with isohexane to afford the title compound as a pale yellow solid (10 mg).

Example 38

6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -1- (iso Propyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-6-methyl-1- (isopropyl) -2,4-dioxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Silver cyanate (13.5 g) suspended in anhydrous toluene (90 ml) was treated dropwise with acetyl chloride (5.34 ml) under nitrogen and stirred vigorously for 30 minutes. The product of Example 8, step a) (23 g) dissolved in anhydrous toluene (15 ml) was added and the mixture was stirred for 72 hours. Ether (360 ml) was added and the insoluble material was filtered off and washed with a small volume of ether. The combined organic solutions were washed with saturated sodium bicarbonate solution, dried and evaporated. The residue was treated with sodium methoxide solution (25% by weight, 64 ml) in methanol for 72 hours at room temperature. The reaction was ice cooled, treated with trimethylsilyl chloride (50.8 ml) and stirred overnight at room temperature. All volatiles were removed in vacuo and the residue was partitioned between water and ethyl acetate. Chromatography the residue obtained by drying and evaporation of the organic solution Photography (SiO _2/2: 1 isohexane-ethyl acetate then 3: 2 isohexane-ethyl acetate) was isolated the title compound (12.2 g).

b) 3-ethyl-1,2,3,4-tetrahydro-6-methyl-1- (isopropyl) -2,4-dioxo-thieno [2,3-d] pyrimidine-5-car Acids, methyl esters

The product of part a) (0.5 g), potassium carbonate (0.34 g), ethyl iodide (0.17 ml), DMF (5 ml) and acetone (5 ml) were heated at 50 ° C. for 16 hours. The reaction mixture was quenched with water (5 ml) and extracted with ethyl acetate. The organic extract was dried (MgSO ₄ ) and concentrated in vacuo. And the residue chromatographed _{(SiO 2/8:: 1} 1 isohexane-ethyl acetate in dichloromethane) to give the title compound as a pale yellow oil.

c) 6- (bromomethyl) -3-ethyl-1,2,3,4-tetrahydro-1- (isopropyl) -2,4-dioxo-thieno [2,3-d] pyrimidine -5-carboxylic acid, methyl ester

The title compound was prepared using the product of part b) according to the method of Example 22, part a).

d) 6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-ethyl-1,2,3,4-tetrahydro-1- (isopropyl) -2,4-dioxo -Thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

The title compound was prepared using the product of part c) according to the method of Example 26, part a).

e) 6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -1- (Isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

The product of part d) (0.6 mmol), diethyl chlorophosphate (0.09 ml), 1-hydroxybenzotriazole (0.08 g), triethylamine (0.1 ml) and acetonitrile (6 ml) were mixed for 30 minutes. Was stirred. Example 1, part b) product (0.08 g) was added and the mixture was stirred for 16 h. Potassium carbonate was added to quench the reaction. The reaction mixture was purified by SiO ₂ chromatography eluting with THF: methanol (98: 2) to afford a yellow foam which was further purified by reverse phase HPLC to give the title compound as a white solid (30 mg).

Example 39

5-[(45) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (trifluoromethyl) phenylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -2,4-dioxo-6- [2- (trifluoromethyl) phenylmethyl] -thieno [2 , 3-d] pyrimidine-5-carboxylic acid

5-Bromo-3-methyl-1- (isobutyl) -6- [2- (trifluoromethyl) phenylmethyl] -thieno [2,3-d] pyrimidine-2 in THF (60 ml) To a solution of, 4 (1H, 3H) -dione (WO 0183489) isopropylmagnesium chloride (2M solution in THF, 3.35 ml) was added dropwise at 0 ° C. under nitrogen. After 5 minutes, the mixture was treated with a carbon dioxide stream for 10 minutes. The reaction mixture was quenched with water, acidified with 2N HCl and extracted into ethyl acetate (x3). The combined organic extracts were washed with dilute HCl, brine, dried (MgSO ₄ ) and concentrated in vacuo to afford the title compound as a yellow solid (2.48 g).

MS (ES) 441 [M + H] ⁺

b) 5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (trifluoromethyl) phenylmethyl]- Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the product of part a) according to the method of Example 1, part g).

Example 40

5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazole-1- Ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

a) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazol-1-ylmethyl] -2,4-di Oxo-thieno [2,3-d] pyrimidine-5-carboxylic acid, methyl ester

Example 13 The title compound was prepared using the product of Example 3, part b) and 2-methylthioimidazole according to the method of vi), part a).

b) 1,2,3,4-tetrahydro-3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazol-1-ylmethyl] -2,4-di Oxo-thieno [2,3-d] pyrimidine-5-carboxylic acid

Prepared using the product of part a) according to the method of Example 3, part d).

MS (ESI) 409 [M + H] ⁺

c) 5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazole- 1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione

Prepared using the product of part b) according to the method of example 3, part e).

MS (APCI) 480

Claims (16)

A compound of formula 1, or a pharmaceutically acceptable salt or prodrug thereof. <Formula 1> In the formula, R ¹ and R ² are each independently C _1-6 alkyl, C _3-6 alkenyl, C _3-6 cycloalkylC _1-3 alkyl or C _3-6 cycloalkyl, each of which is optionally 1 to 3 May be substituted with a halogen atom; R ³ is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group; Q is -CO- or -C (R ⁴ ) (R ⁵ )-, wherein R ⁴ is a hydrogen atom or C _1-4 alkyl and R ⁵ is a hydrogen atom or a hydroxy group; Ar may be heteroatoms of up to 4 ring atoms independently selected from nitrogen, oxygen and sulfur, and the ring system is independently C _1-4 alkyl (optionally substituted with 1, 2 or 3 hydroxy groups), C _1-4 Alkoxy, halogen, haloalkyl, dihaloalkyl, trihaloalkyl, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylthio, C _1-4 alkoxycarbonyl, C _2-4 alkanoyl, oxo , Thioxo, nitro, cyano, -N (R ⁶ ) R ⁷ and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , hydroxy, C _1-4 alkylsulfonyl, C _1-4 alkylsulfinyl 5 or containing up to 4 heteroatoms selected from carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, and independently nitrogen, oxygen and sulfur; or A 5-10 membered aromatic ring system optionally substituted with one or more substituents selected from 6 membered aromatic rings; p is 1 to 4; R ⁶ and R ⁷ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring; R ⁸ and R ⁹ are each independently a hydrogen atom, C _1-4 alkanoyl or C _1-4 alkyl, or together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring. The compound of claim 1, wherein R ² is methyl or ethyl. The compound of claim 1 or 2, wherein R ¹ is ethyl, n-propyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropylmethyl, trifluoromethyl 2,2,2- Trifluoroethyl, 2-chloroethyl, 2-chloropropyl or 3,3,3-trifluoropropyl. The compound of any one of claims 1-3, wherein Q is -CO- or -CH _2- . 5. The compound of claim 1, wherein Ar contains at least one ring nitrogen. The compound of any one of claims 1-5, wherein Ar contains two or more ring nitrogens. The compound according to any one of claims 1 to 4, wherein Ar is imidazolyl, pyrazolyl, pyrrolyl, isoxazolyl, phenyl, quinolyl, indolyl, wherein each ring system is optionally substituted according to claim 1. , Benzimidazolyl, indazolyl, benztriazolyl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzoxazolyl, pyrrolo [2,3-b] pyridyl, imidazo [1,2 -a] pyridyl, imidazo [4,5-b] pyridyl, 2,3-dihydrothiazolo [5,4-b] pyridyl, 2,3-dihydropyrazinyl, 2,3-di A compound selected from hydrobenzothiazolyl and 2,3-dihydrobenzimidazolyl. 8. The compound of claim 1, wherein Ar is independently C _1-4 alkyl (optionally substituted with 1 or 2 hydroxy groups), C _1-4 alkoxy, halogen, trihaloalkyl, C _1-4 alkylthio, C _2-4 alkanoyl, oxo, thioxo, cyano and-(CH ₂ ) _p N (R ⁸ ) R ⁹ , where p is 1 or 2, hydroxy, C _{1- 4} alkylsulfonyl, carbamoyl, C _1-4 alkylcarbamoyl, di- (C _1-4 alkyl) carbamoyl, carboxy, and up to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur Compound substituted with 1, 2 or 3 substituents selected from containing 5 or 6 membered aromatic rings. The method of claim 1, (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione; (R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (4-quinolinylcarbonyl) thieno [2 , 3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) methyl] -1- (2- Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(1H-pyrrolo [2,3-b] Pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-indol-3-yl) carbonyl] -1- (2 -Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (1-methylethyl) -6- (1H-pyrrolo [2,3-b] pyridine -3-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [4,5-dichloro-2-oxo-3 (2H) -thiazolylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1 -(2-methylpropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6-[(3,5-dimethyl-1H-pyrazol-4-yl) methyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1-isobutyl-3 Methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -1-isobutyl-3-methyl-6- [1,3,5-trimethyl-1H-pyrazol-4-yl Methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (R) -6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl) methyl] -5- [4-hydroxy-isoxazolidin-2-ylcarbonyl]- 3-methyl-1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl-1H-benzimidazol-1-yl) methyl] -1- ( 2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6-[(2-ethyl-1H-benzimidazol-1-yl) methyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- ( 2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-propyl-1H-benzimidazole-1 -Yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2- (methylthio) -1H-benzimidazole -1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-amino-1H-benzimidazol-1-ylmethyl] -1- (2- Methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2,4,5-trichloro-1H- Imidazol-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2-thioxo-3 (2H) -benzothia Zolylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [4-chloro-2-oxo-3 (2H) -Thiazolylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- [2-oxo-1,3-benzoxazole-3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6-[(2-oxo [1,3] thiazolo [ 5,4-b] pyridin-1 (2H) -yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (1H-1,2,3-benzotriazole- 1-ylmethyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- (1H-pyrrolo [2,3-b] pyridine -1-ylmethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -1- [1,2,3,4-tetrahydro-5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -2 , 4-dioxothieno [2,3-d] pyrimidin-6-ylmethyl) -1H-indole-5-carbonitrile; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- [2-oxo-1,3-benzothiazole- 3 (2H) -ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (2-methylpropyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2-methyl-1H-indol-3-ylmethyl] -1- (2-methylpropyl ) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -3H-imidazo [4,5-b] pyridine-3 -Ylmethyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6- [2- (methylamino) -1H-benzimidazol-1-ylmethyl] -1- (1-methylethyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -5- [4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl- 1- (1-methylethyl) thieno [2,3-d] pyrimidine-5-carboxamide; (S) -6- [3,5-diethyl-1H-pyrazol-4-ylmethyl] -5- {4-hydroxyisoxazolidin-2-yl] carbonyl} -3-methyl-1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [3- (1,1-dimethylethyl) -5-methyl-1H-pyrazol-4-ylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl- 3-methyl-1- (2-methylpropyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6- [2-methyl-4-quinolinylmethyl] thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [6-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [8-fluoro-4-quinolinylmethyl] -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (2-methylpropyl) -6- (5-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1-propyl-6- (quinolin-4-ylmethyl) thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione; (S) -5- {4-hydroxyisoxazolidin-2-ylcarbonyl} -3-methyl-1- (1-methylethyl) -6- (4-quinolinylmethyl) thieno [2, 3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (R) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (2-methylpropyl) -6-[(2-methyl-1H-pyrrolo [2, 3-b] pyridin-3-yl) methyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3-oxo -Pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-6-[(2-methyl) -1H-pyrrolo [2,3-b] pyridine-3- Yl) methyl] -1-propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -Propyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propyl-6- [2-amino-1H-benzimidazol-1-ylmethyl] -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -6- [2- (hydroxymethyl) -1H-benzimidazol-1-ylmethyl] -3-methyl-1 -(Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-amino-1H-benzimidazol-1-ylmethyl ] Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-1-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isopropyl) -6- [2-methyl-1H-pyrrolo [2,3-b ] Pyridin-3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [4,5-dichloro-2- (hydroxymethyl) -1H-imidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl]- 3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [3,5-dimethyl-1H-pyrazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (iso Butyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3- Methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1-propylthier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isopropyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; (S) -6- [3,5-dimethylisoxazol-4-ylmethyl] -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [4,5-dichloro-2-methyl-1H-imidazol-1-ylmethyl] -1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl]- 3-methyl-thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- (1H-pyrrolo [2,3-b] pyridin-3-ylmethyl ) -Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-propyl-1H-benzimidazol-1-ylmethyl] -thier No [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-oxo-3 (2H) -benzothiazolylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [2-methyl-1H-pyrrolo [2,3-b] pyridine- 3-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 1-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-6- [5-cyano-1H-indol-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -6- [1-isopropyl-3,5-dimethyl-1H-pyrazole-4- Ylmethyl] -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1- (isobutyl) -3-methyl-6- [5-methyl-3-phenyl-1H-pyrazole-4 -Ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-3-methyl-6- [5-methyl-3- (trifluoromethyl) -1H-pyra Zol-4-ylmethyl] thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl-6- [3-isopropyl-5-methyl-1H-pyrazol-4-ylmethyl]- 3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -1-isobutyl -3-methylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl- 1-propylthieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- (1H-1,2,3-benzotriazol-1-ylmethyl) -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl)- Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4H) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isopropyl) -6-[(2-oxothiazolo [5,4-b] pyridine-1 (2H ) -Yl) methyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (Isopropyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [5,6-difluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-ylmethyl] -5-[(4S) -4-hydroxy-2-isoxazole Ridinylcarbonyl] -3-methyl-1- (isobutyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -6- (imidazo [1,2-a] pyridin-3-ylmethyl) -1-isobutyl-3-methyl Thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 3-methyl-6- [2-methylindol-3-ylmethyl] -1- (isobutyl) -5- (tetrahydroisoxazine-2-ylcarbonyl) -thieno [2,3-d] pyrid Midine-2,4 (1H, 3H) -dione; 6- [2-bromo-4,5-dichloro-1H-imidazol-1-ylmethyl] -5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- ( Isobutyl) thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazo [4, 5-b] pyridin-1-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxyisoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -3H-imidazo [4,5-b] Pyridin-3-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 6- [3,5-dimethyl-1H-pyrazol-4-ylmethyl] -3-ethyl-5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -1- (iso Propyl) -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (trifluoromethyl) phenylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; 5-[(4S) -4-hydroxy-2-isoxazolidinylcarbonyl] -3-methyl-1- (isobutyl) -6- [2- (methylthio) -1H-imidazole-1- Ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; or (S) -5- [4-hydroxyisoxazolidin-2-ylcarbonyl] -3-methyl-1- (isobutyl) -6- [2,3-dihydro-6-methyl-3-oxo -Pyrazin-2-ylmethyl] -thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione; Phosphorus compounds or pharmaceutically acceptable salts thereof. a) a method of reacting a compound of formula 10 with isoxazolidine or tetrahydroisoxazine, each optionally substituted with one hydroxy group; b) when Q is methylene, reacting a compound of Formula 11 with a compound of Formula Ar; c) when Q is methylene, reducing the compound of formula 12; d) a process for preparing Ar by primary ring synthesis by reacting a compound of formula 11 or 13; e) a method of reacting a compound of Formula 14 with R ¹ -L ² Compounds of formula (I) as defined in claim 1 or compounds of formula (I) as defined in claim 1 wherein at least one functional group is protected using any one of the methods a), b), c) Or d) later, converting the compound of formula 1 to another compound of formula 1 and / or preparing a pharmaceutically acceptable salt or solvate thereof. <Formula 10> <Formula 11> <Formula 12> <Formula 13> <Formula 14> Wherein L and L ² are leaving groups and R ¹ , R ² , R ³ , Q and Ar are as defined in claim 1. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable adjuvant, diluent or carrier. 10. A compound according to any one of claims 1 to 9 for use in therapy. Use of the compound according to any one of claims 1 to 9 in the manufacture of a medicament for inhibiting the proliferation of T cells. A method of inhibiting proliferation of T cells comprising administering to a patient a therapeutically effective amount of a compound of formula 1 according to claim 1. An immunosuppressive method comprising administering to a patient a therapeutically effective amount of a compound of formula 1 according to claim 1. Treating or at risk of reversible obstructive airway disease in a patient comprising administering a therapeutically effective amount of a compound of formula 1 according to claim 1 to a patient suffering from or at risk of having a reversible obstructive airway disease How to reduce it.